WO2023051495A1 - Composés isoquinolinone et quinazolinone, et composition et utilisation de ceux-ci - Google Patents
Composés isoquinolinone et quinazolinone, et composition et utilisation de ceux-ci Download PDFInfo
- Publication number
- WO2023051495A1 WO2023051495A1 PCT/CN2022/121567 CN2022121567W WO2023051495A1 WO 2023051495 A1 WO2023051495 A1 WO 2023051495A1 CN 2022121567 W CN2022121567 W CN 2022121567W WO 2023051495 A1 WO2023051495 A1 WO 2023051495A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- deuterated
- haloalkyl
- independently
- alkoxy
- Prior art date
Links
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 title abstract description 11
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title abstract description 3
- 239000000203 mixture Substances 0.000 title description 377
- 150000001875 compounds Chemical class 0.000 claims abstract description 150
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims abstract description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 39
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 230000000694 effects Effects 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 21
- 208000035475 disorder Diseases 0.000 claims abstract description 13
- 230000001404 mediated effect Effects 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- -1 methoxy, ethoxy Chemical group 0.000 claims description 429
- 125000000217 alkyl group Chemical group 0.000 claims description 274
- 229910052805 deuterium Inorganic materials 0.000 claims description 115
- 125000000623 heterocyclic group Chemical group 0.000 claims description 114
- 125000001072 heteroaryl group Chemical group 0.000 claims description 105
- 229910052739 hydrogen Inorganic materials 0.000 claims description 90
- 125000003545 alkoxy group Chemical group 0.000 claims description 89
- 125000003118 aryl group Chemical group 0.000 claims description 78
- 229910052731 fluorine Inorganic materials 0.000 claims description 77
- 229910052801 chlorine Inorganic materials 0.000 claims description 76
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 74
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 60
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 59
- 229910052794 bromium Inorganic materials 0.000 claims description 58
- 229910052740 iodine Inorganic materials 0.000 claims description 58
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 45
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 43
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 40
- 238000006467 substitution reaction Methods 0.000 claims description 31
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 30
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 30
- 125000006642 (C1-C6) cyanoalkyl group Chemical group 0.000 claims description 27
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 27
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 24
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 24
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 18
- 239000012453 solvate Substances 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 206010052779 Transplant rejections Diseases 0.000 claims description 15
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 208000002193 Pain Diseases 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
- 208000027866 inflammatory disease Diseases 0.000 claims description 9
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 8
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 8
- 208000034486 Multi-organ failure Diseases 0.000 claims description 8
- 206010033645 Pancreatitis Diseases 0.000 claims description 8
- 208000017169 kidney disease Diseases 0.000 claims description 8
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- 208000023504 respiratory system disease Diseases 0.000 claims description 8
- 230000019100 sperm motility Effects 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 7
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
- 208000010718 Multiple Organ Failure Diseases 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 125000002883 imidazolyl group Chemical group 0.000 claims description 6
- 208000004296 neuralgia Diseases 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 125000004306 triazinyl group Chemical group 0.000 claims description 6
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims description 5
- 208000004852 Lung Injury Diseases 0.000 claims description 5
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 150000001924 cycloalkanes Chemical class 0.000 claims description 5
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 231100000515 lung injury Toxicity 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 208000007536 Thrombosis Diseases 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 4
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 208000008035 Back Pain Diseases 0.000 claims description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 206010066476 Haematological malignancy Diseases 0.000 claims description 3
- 206010065390 Inflammatory pain Diseases 0.000 claims description 3
- 208000004554 Leishmaniasis Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 3
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 230000005713 exacerbation Effects 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 125000004969 haloethyl group Chemical group 0.000 claims description 2
- 125000004970 halomethyl group Chemical group 0.000 claims description 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 241000228212 Aspergillus Species 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 9
- 102000020233 phosphotransferase Human genes 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 5
- 102000001253 Protein Kinase Human genes 0.000 abstract description 4
- 108060006633 protein kinase Proteins 0.000 abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 463
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 323
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 221
- 239000000243 solution Substances 0.000 description 177
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 166
- 239000012267 brine Substances 0.000 description 142
- 239000007787 solid Substances 0.000 description 137
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 114
- 235000019439 ethyl acetate Nutrition 0.000 description 102
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 98
- 238000004440 column chromatography Methods 0.000 description 98
- 239000007832 Na2SO4 Substances 0.000 description 94
- 229910052938 sodium sulfate Inorganic materials 0.000 description 94
- 235000011152 sodium sulphate Nutrition 0.000 description 94
- 238000001816 cooling Methods 0.000 description 84
- 239000012044 organic layer Substances 0.000 description 81
- 239000012074 organic phase Substances 0.000 description 77
- 239000011734 sodium Substances 0.000 description 74
- 230000002829 reductive effect Effects 0.000 description 65
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 62
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 43
- 239000003921 oil Substances 0.000 description 43
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 42
- 125000004093 cyano group Chemical group *C#N 0.000 description 42
- 239000010410 layer Substances 0.000 description 42
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 38
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 38
- XMRIUEGHBZTNND-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC=NC2=C(C(=O)N)C=NN21 XMRIUEGHBZTNND-UHFFFAOYSA-N 0.000 description 36
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 35
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 33
- 239000002585 base Substances 0.000 description 31
- 238000006243 chemical reaction Methods 0.000 description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 238000000034 method Methods 0.000 description 27
- 108091007960 PI3Ks Proteins 0.000 description 26
- 102000038030 PI3Ks Human genes 0.000 description 26
- 238000003756 stirring Methods 0.000 description 26
- 125000001424 substituent group Chemical group 0.000 description 25
- 238000002953 preparative HPLC Methods 0.000 description 24
- RGVPAUFBNKASEL-UHFFFAOYSA-N 2-aminopyrazolo[1,5-a]pyrimidine-3-carboxylic acid Chemical compound C1=CC=NC2=C(C(O)=O)C(N)=NN21 RGVPAUFBNKASEL-UHFFFAOYSA-N 0.000 description 23
- 125000004432 carbon atom Chemical group C* 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- 239000012299 nitrogen atmosphere Substances 0.000 description 22
- MZINZXIFJMLTOK-NSHDSACASA-N 3-[(1s)-1-aminoethyl]-8-chloro-2-phenylisoquinolin-1-one Chemical compound C[C@H](N)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 MZINZXIFJMLTOK-NSHDSACASA-N 0.000 description 21
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 21
- 238000010898 silica gel chromatography Methods 0.000 description 21
- 125000004429 atom Chemical group 0.000 description 20
- 239000000706 filtrate Substances 0.000 description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 19
- 125000006413 ring segment Chemical group 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 14
- 239000012230 colorless oil Substances 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000012043 crude product Substances 0.000 description 12
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000012065 filter cake Substances 0.000 description 11
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 11
- 235000019270 ammonium chloride Nutrition 0.000 description 10
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 10
- ULAUDORZMUYTSV-UHFFFAOYSA-N 2-amino-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid Chemical compound N1=C(C)C=CN2N=C(N)C(C(O)=O)=C21 ULAUDORZMUYTSV-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- RACKOVAPLUVOJA-UHFFFAOYSA-N 4-ethynyl-1-methylpyrazole Chemical compound CN1C=C(C#C)C=N1 RACKOVAPLUVOJA-UHFFFAOYSA-N 0.000 description 7
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 7
- 108010029485 Protein Isoforms Proteins 0.000 description 7
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- YLRKWLSCHSHVRE-UHFFFAOYSA-N 6,7-dihydro-5h-pyrrolo[1,2-a]imidazole-3-carbaldehyde Chemical compound C1CCN2C(C=O)=CN=C21 YLRKWLSCHSHVRE-UHFFFAOYSA-N 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000003282 alkyl amino group Chemical group 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- YLFBFPXKTIQSSY-UHFFFAOYSA-N dimethoxy(oxo)phosphanium Chemical compound CO[P+](=O)OC YLFBFPXKTIQSSY-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- PWQIGBOSLQHOBT-ZETCQYMHSA-N tert-butyl n-[(2s)-1-[methoxy(methyl)amino]-1-oxopropan-2-yl]carbamate Chemical compound CON(C)C(=O)[C@H](C)NC(=O)OC(C)(C)C PWQIGBOSLQHOBT-ZETCQYMHSA-N 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
- 101710093328 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 5
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 description 5
- 101710125691 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 239000002260 anti-inflammatory agent Substances 0.000 description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 description 5
- 230000001028 anti-proliverative effect Effects 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 150000001602 bicycloalkyls Chemical class 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 5
- HRAWNPOJGRIJSB-UHFFFAOYSA-N ethyl 3,5-diamino-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C(N)=NNC=1N HRAWNPOJGRIJSB-UHFFFAOYSA-N 0.000 description 5
- YCAVTOUTYRMOGQ-UHFFFAOYSA-N ethyl 7-[3-[[3-(trifluoromethyl)benzoyl]amino]phenyl]pyrazolo[1,5-a]pyrimidine-3-carboxylate Chemical compound C=1C=NC2=C(C(=O)OCC)C=NN2C=1C(C=1)=CC=CC=1NC(=O)C1=CC=CC(C(F)(F)F)=C1 YCAVTOUTYRMOGQ-UHFFFAOYSA-N 0.000 description 5
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 229940043355 kinase inhibitor Drugs 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical compound C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 229910052693 Europium Inorganic materials 0.000 description 4
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 4
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 4
- 229910010082 LiAlH Inorganic materials 0.000 description 4
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 description 4
- 101710204747 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 150000001345 alkine derivatives Chemical group 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 4
- 229940121354 immunomodulator Drugs 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 4
- FORPZPRMQFFKAV-UHFFFAOYSA-N methyl 4-oxo-6-trimethylsilylhex-5-ynoate Chemical compound COC(=O)CCC(=O)C#C[Si](C)(C)C FORPZPRMQFFKAV-UHFFFAOYSA-N 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical group O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 description 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 description 4
- 235000011009 potassium phosphates Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 239000012089 stop solution Substances 0.000 description 4
- 238000001308 synthesis method Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 4
- NYPFNJOTVWTWAF-UHFFFAOYSA-N (2-oxopyrrolidin-1-yl)azanium;chloride Chemical compound Cl.NN1CCCC1=O NYPFNJOTVWTWAF-UHFFFAOYSA-N 0.000 description 3
- RJFJRYVMVNICCP-MNOVXSKESA-N (2s,4r)-4-phenylmethoxypyrrolidine-2-carboxylic acid Chemical compound C1N[C@H](C(=O)O)C[C@H]1OCC1=CC=CC=C1 RJFJRYVMVNICCP-MNOVXSKESA-N 0.000 description 3
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- FUTKYPVWTIJNDA-UHFFFAOYSA-N 1-(benzhydrylideneamino)pyrrolidin-2-one Chemical compound O=C1CCCN1N=C(C=1C=CC=CC=1)C1=CC=CC=C1 FUTKYPVWTIJNDA-UHFFFAOYSA-N 0.000 description 3
- OZFGRQLUQFPWPR-UHFFFAOYSA-N 1-[(2,4-dimethoxyphenyl)methyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound COC1=CC(OC)=CC=C1CN1C(=O)CC(C(O)=O)C1 OZFGRQLUQFPWPR-UHFFFAOYSA-N 0.000 description 3
- KYJBHEXXMLSDOT-UHFFFAOYSA-N 1-methyl-5-oxopyrrolidine-3-carbaldehyde Chemical compound CN1CC(C=O)CC1=O KYJBHEXXMLSDOT-UHFFFAOYSA-N 0.000 description 3
- CUXKNQDOYULMKG-UHFFFAOYSA-N 2,3-dihydropyrazolo[5,1-b][1,3]oxazol-6-ylmethanol Chemical compound O1CCN2N=C(CO)C=C21 CUXKNQDOYULMKG-UHFFFAOYSA-N 0.000 description 3
- BBSSEVYJISPIML-UHFFFAOYSA-N 2,3-dihydropyrazolo[5,1-b][1,3]oxazole Chemical compound N1=CC=C2OCCN21 BBSSEVYJISPIML-UHFFFAOYSA-N 0.000 description 3
- HRWUBJRFWUWTLF-UHFFFAOYSA-N 2,3-dihydropyrazolo[5,1-b][1,3]oxazole-6-carbaldehyde Chemical compound O1CCN2N=C(C=O)C=C21 HRWUBJRFWUWTLF-UHFFFAOYSA-N 0.000 description 3
- QPJSLFGBOVFHAF-UHFFFAOYSA-N 2-(4-bromopyrazol-1-yl)ethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCN1C=C(Br)C=N1 QPJSLFGBOVFHAF-UHFFFAOYSA-N 0.000 description 3
- VINPZIJQPQGZEJ-JTQLQIEISA-N 2-[(1s)-1-aminoethyl]-5-bromo-3-phenylquinazolin-4-one Chemical compound C[C@H](N)C1=NC2=CC=CC(Br)=C2C(=O)N1C1=CC=CC=C1 VINPZIJQPQGZEJ-JTQLQIEISA-N 0.000 description 3
- SVNWFJQSJIUROM-UHFFFAOYSA-N 2-amino-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid Chemical compound C1=C(F)C=NC2=C(C(O)=O)C(N)=NN21 SVNWFJQSJIUROM-UHFFFAOYSA-N 0.000 description 3
- GZFYDEITHJPTAL-UHFFFAOYSA-N 2-bromo-3-fluoro-6-nitro-N-phenylbenzamide Chemical compound BrC1=C(C(=O)NC2=CC=CC=C2)C(=CC=C1F)[N+](=O)[O-] GZFYDEITHJPTAL-UHFFFAOYSA-N 0.000 description 3
- WHOTUUFDHGVXSG-UHFFFAOYSA-N 2-bromo-3-fluoro-6-nitrobenzoic acid Chemical compound OC(=O)C1=C(Br)C(F)=CC=C1[N+]([O-])=O WHOTUUFDHGVXSG-UHFFFAOYSA-N 0.000 description 3
- CPCKYTVKZDZSBA-UHFFFAOYSA-N 2-chloro-6-methyl-n-phenylbenzamide Chemical compound CC1=CC=CC(Cl)=C1C(=O)NC1=CC=CC=C1 CPCKYTVKZDZSBA-UHFFFAOYSA-N 0.000 description 3
- CEFMMQYDPGCYMG-UHFFFAOYSA-N 2-chloro-6-methylbenzoic acid Chemical compound CC1=CC=CC(Cl)=C1C(O)=O CEFMMQYDPGCYMG-UHFFFAOYSA-N 0.000 description 3
- BYXFOXCVQUVRAM-UHFFFAOYSA-N 2-chloro-n-cyclopropyl-6-methylbenzamide Chemical compound CC1=CC=CC(Cl)=C1C(=O)NC1CC1 BYXFOXCVQUVRAM-UHFFFAOYSA-N 0.000 description 3
- VUYWLEYGTFTTMN-UHFFFAOYSA-N 3-bromo-6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazine Chemical compound C1COCC2=C(Br)C=NN21 VUYWLEYGTFTTMN-UHFFFAOYSA-N 0.000 description 3
- LWKRQSQTGUGFAU-UHFFFAOYSA-N 3-bromo-6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine Chemical compound C1CCOC2=C(Br)C=NN21 LWKRQSQTGUGFAU-UHFFFAOYSA-N 0.000 description 3
- SOXIPNKHMJEZMN-UHFFFAOYSA-N 3-ethynylazetidine Chemical compound C#CC1CNC1 SOXIPNKHMJEZMN-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- AEJLDXOAORTQER-UHFFFAOYSA-N 4-(hydroxymethyl)-1-methylpyrrolidin-2-one Chemical compound CN1CC(CO)CC1=O AEJLDXOAORTQER-UHFFFAOYSA-N 0.000 description 3
- WTVAENXFNMHDMU-UHFFFAOYSA-N 4-bromopyridin-1-ium-1-amine Chemical compound N[N+]1=CC=C(Br)C=C1 WTVAENXFNMHDMU-UHFFFAOYSA-N 0.000 description 3
- RACKOVAPLUVOJA-BMSJAHLVSA-N 4-ethynyl-1-(trideuteriomethyl)pyrazole Chemical compound C(#C)C=1C=NN(C=1)C([2H])([2H])[2H] RACKOVAPLUVOJA-BMSJAHLVSA-N 0.000 description 3
- IASRYLKZYZPWRV-UHFFFAOYSA-N 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine Chemical compound C1CCOC2=CC=NN21 IASRYLKZYZPWRV-UHFFFAOYSA-N 0.000 description 3
- ZWETXQBHVRWLPW-UHFFFAOYSA-N 6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CN2CCCC2=N1 ZWETXQBHVRWLPW-UHFFFAOYSA-N 0.000 description 3
- XYSNKIFLZNVECF-UHFFFAOYSA-N 6-amino-2-bromo-3-fluoro-N-phenylbenzamide Chemical compound NC1=CC=C(C(=C1C(=O)NC1=CC=CC=C1)Br)F XYSNKIFLZNVECF-UHFFFAOYSA-N 0.000 description 3
- RDJCODQKUJYLLX-UHFFFAOYSA-N 6-chloro-2-methyl-3-nitro-n-phenylbenzamide Chemical compound CC1=C([N+]([O-])=O)C=CC(Cl)=C1C(=O)NC1=CC=CC=C1 RDJCODQKUJYLLX-UHFFFAOYSA-N 0.000 description 3
- VMZHBAGNUZAWTI-UHFFFAOYSA-N 6-chloro-2-methyl-3-nitrobenzoic acid Chemical compound CC1=C([N+]([O-])=O)C=CC(Cl)=C1C(O)=O VMZHBAGNUZAWTI-UHFFFAOYSA-N 0.000 description 3
- BQKYQCLAEACSBR-UHFFFAOYSA-N 6-chloro-3-fluoro-2-methyl-n-phenylbenzamide Chemical compound CC1=C(F)C=CC(Cl)=C1C(=O)NC1=CC=CC=C1 BQKYQCLAEACSBR-UHFFFAOYSA-N 0.000 description 3
- XOXBTEVVYDCNOQ-UHFFFAOYSA-N 7-bromo-2,3-dihydropyrazolo[5,1-b][1,3]oxazole Chemical compound C1COC2=C(Br)C=NN21 XOXBTEVVYDCNOQ-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- ACFBFASMNXFIBF-UHFFFAOYSA-N CCOC(C(NN(CCC1)C1=O)=N)=O Chemical compound CCOC(C(NN(CCC1)C1=O)=N)=O ACFBFASMNXFIBF-UHFFFAOYSA-N 0.000 description 3
- FNQSKPLABBLMKC-UHFFFAOYSA-N CN1CC(C#C)CC1=O Chemical compound CN1CC(C#C)CC1=O FNQSKPLABBLMKC-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LYNLMZCSBPAGIV-UHFFFAOYSA-N N1=C2N(N=C1C(=O)OCC)CCC2 Chemical compound N1=C2N(N=C1C(=O)OCC)CCC2 LYNLMZCSBPAGIV-UHFFFAOYSA-N 0.000 description 3
- 239000012828 PI3K inhibitor Substances 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- UQFQONCQIQEYPJ-QYKNYGDISA-N [2H]C1=CC=NN1C Chemical compound [2H]C1=CC=NN1C UQFQONCQIQEYPJ-QYKNYGDISA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- FZWVFMXBFCGKDG-UHFFFAOYSA-N ethyl 2,3-dihydropyrazolo[5,1-b][1,3]oxazole-6-carboxylate Chemical compound O1CCN2N=C(C(=O)OCC)C=C21 FZWVFMXBFCGKDG-UHFFFAOYSA-N 0.000 description 3
- KZGWPHUWNWRTEP-UHFFFAOYSA-N ethynyl-tri(propan-2-yl)silane Chemical compound CC(C)[Si](C#C)(C(C)C)C(C)C KZGWPHUWNWRTEP-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- OSDRMRSHBFQVJF-UHFFFAOYSA-N methyl 4-hydroxyhex-5-ynoate Chemical compound COC(=O)CCC(O)C#C OSDRMRSHBFQVJF-UHFFFAOYSA-N 0.000 description 3
- ANNCINJMCFHILW-UHFFFAOYSA-N n-(benzhydrylideneamino)-4-chlorobutanamide Chemical compound C=1C=CC=CC=1C(=NNC(=O)CCCCl)C1=CC=CC=C1 ANNCINJMCFHILW-UHFFFAOYSA-N 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- WLKPHJWEIIAIFW-UHFFFAOYSA-N n-nitrosoproline Chemical compound OC(=O)C1CCCN1N=O WLKPHJWEIIAIFW-UHFFFAOYSA-N 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 150000003916 phosphatidylinositol 3,4,5-trisphosphates Chemical class 0.000 description 3
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000007420 radioactive assay Methods 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- UENGYBYGCXKNRF-UHFFFAOYSA-N tert-butyl 3-ethynylazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(C#C)C1 UENGYBYGCXKNRF-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical group S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- LIPGLFARXMXYKK-UHFFFAOYSA-N trimethyl-[2-(1-methylpyrazol-4-yl)ethynyl]silane Chemical compound CN1C=C(C#C[Si](C)(C)C)C=N1 LIPGLFARXMXYKK-UHFFFAOYSA-N 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 2
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 2
- SQHSJJGGWYIFCD-UHFFFAOYSA-N (e)-1-diazonio-1-dimethoxyphosphorylprop-1-en-2-olate Chemical compound COP(=O)(OC)C(\[N+]#N)=C(\C)[O-] SQHSJJGGWYIFCD-UHFFFAOYSA-N 0.000 description 2
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- WXLCDTBTIVJDCE-UHFFFAOYSA-N 1,4-oxazepine Chemical compound O1C=CC=NC=C1 WXLCDTBTIVJDCE-UHFFFAOYSA-N 0.000 description 2
- QPPOMEOQNLTFRU-UHFFFAOYSA-N 1,4-thiazepine Chemical compound S1C=CC=NC=C1 QPPOMEOQNLTFRU-UHFFFAOYSA-N 0.000 description 2
- VJPSRVSSKYBSCQ-UHFFFAOYSA-N 1-[(2,4-dimethoxyphenyl)methyl]-4-(hydroxymethyl)pyrrolidin-2-one Chemical compound COC1=CC(OC)=CC=C1CN1C(=O)CC(CO)C1 VJPSRVSSKYBSCQ-UHFFFAOYSA-N 0.000 description 2
- POXWDTQUDZUOGP-UHFFFAOYSA-N 1h-1,4-diazepine Chemical compound N1C=CC=NC=C1 POXWDTQUDZUOGP-UHFFFAOYSA-N 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- LZMHJTOKNNMHNS-FQEVSTJZSA-N 2-amino-5-methyl-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C[C@H](NC(=O)C1=C2N=C(C)C=CN2N=C1N)C1=CC2=CC=CC(C#CC3=CN(C)N=C3)=C2C(=O)N1C1=CC=CC=C1 LZMHJTOKNNMHNS-FQEVSTJZSA-N 0.000 description 2
- MWYDSXOGIBMAET-UHFFFAOYSA-N 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide Chemical compound NC1=NC=C(C=N1)C(=O)N=C1N=C2C(=C(C=CC2=C2N1CCN2)OCCCN1CCOCC1)OC MWYDSXOGIBMAET-UHFFFAOYSA-N 0.000 description 2
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 2
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 2
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 2
- BIAVXOOUJFEMLT-QMMMGPOBSA-N 3-[(1s)-1-aminoethyl]-8-chloro-2-cyclopropylisoquinolin-1-one Chemical compound C[C@H](N)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1CC1 BIAVXOOUJFEMLT-QMMMGPOBSA-N 0.000 description 2
- QIAKZVHRSDMVHS-JTQLQIEISA-N 3-[(1s)-1-aminoethyl]-8-chloro-5-fluoro-2-phenylisoquinolin-1-one Chemical compound C[C@H](N)C1=CC2=C(F)C=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 QIAKZVHRSDMVHS-JTQLQIEISA-N 0.000 description 2
- RRYSNPGWQMUQBW-JTQLQIEISA-N 3-[(1s)-1-aminoethyl]-8-chloro-7-fluoro-2-phenylisoquinolin-1-one Chemical compound C[C@H](N)C1=CC2=CC=C(F)C(Cl)=C2C(=O)N1C1=CC=CC=C1 RRYSNPGWQMUQBW-JTQLQIEISA-N 0.000 description 2
- NUSZTECVBVJWSK-UHFFFAOYSA-N 3-amino-6-chloro-2-methyl-n-phenylbenzamide Chemical compound CC1=C(N)C=CC(Cl)=C1C(=O)NC1=CC=CC=C1 NUSZTECVBVJWSK-UHFFFAOYSA-N 0.000 description 2
- VDKFNBYHNNAJBC-UHFFFAOYSA-N 3-ethynyloxetan-3-ol Chemical compound C#CC1(O)COC1 VDKFNBYHNNAJBC-UHFFFAOYSA-N 0.000 description 2
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 2
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 2
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 2
- PJCCSZUMZMCWSX-UHFFFAOYSA-N 4,4-Dimethoxy-2-butanone Chemical compound COC(OC)CC(C)=O PJCCSZUMZMCWSX-UHFFFAOYSA-N 0.000 description 2
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 2
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 2
- RTZLJDDSFCFBML-UHFFFAOYSA-N 5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carbaldehyde Chemical compound C1CCN2N=C(C=O)C=C21 RTZLJDDSFCFBML-UHFFFAOYSA-N 0.000 description 2
- LATQYZZGNADRLH-UHFFFAOYSA-N 5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-3-carbaldehyde Chemical compound C1CCC2=C(C=O)C=NN21 LATQYZZGNADRLH-UHFFFAOYSA-N 0.000 description 2
- NWANPMDGPFSYMR-UHFFFAOYSA-N 5-ethynyl-5-methyloxolan-2-one Chemical compound C#CC1(C)CCC(=O)O1 NWANPMDGPFSYMR-UHFFFAOYSA-N 0.000 description 2
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000002909 Aspergillosis Diseases 0.000 description 2
- 208000036641 Aspergillus infections Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- UQFQONCQIQEYPJ-UHFFFAOYSA-N N-methylpyrazole Chemical compound CN1C=CC=N1 UQFQONCQIQEYPJ-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229940124607 PI3Kα inhibitor Drugs 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229960005475 antiinfective agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 239000012954 diazonium Substances 0.000 description 2
- 150000001989 diazonium salts Chemical class 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 2
- 125000000532 dioxanyl group Chemical group 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- FKBUOZSNISVNHI-UHFFFAOYSA-N ethyl 2-aminopyrazolo[1,5-a]pyrimidine-3-carboxylate Chemical compound C1=CC=NC2=C(C(=O)OCC)C(N)=NN21 FKBUOZSNISVNHI-UHFFFAOYSA-N 0.000 description 2
- XHUWDDXMORFULQ-UHFFFAOYSA-N ethyl 2h-pyrimidine-1-carboxylate Chemical compound CCOC(=O)N1CN=CC=C1 XHUWDDXMORFULQ-UHFFFAOYSA-N 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- DBTNVRCCIDISMV-UHFFFAOYSA-L lithium;magnesium;propane;dichloride Chemical compound [Li+].[Mg+2].[Cl-].[Cl-].C[CH-]C DBTNVRCCIDISMV-UHFFFAOYSA-L 0.000 description 2
- 231100000516 lung damage Toxicity 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- VMVWFJDZNOOKIW-UHFFFAOYSA-N methyl 4-hydroxy-6-trimethylsilylhex-5-ynoate Chemical compound COC(=O)CCC(O)C#C[Si](C)(C)C VMVWFJDZNOOKIW-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 125000003551 oxepanyl group Chemical group 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 150000002940 palladium Chemical class 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000013094 purity test Methods 0.000 description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003883 substance clean up Methods 0.000 description 2
- QMBFNSLJIANSKV-LBPRGKRZSA-N tert-butyl N-[(2S)-1-[3-bromo-4-fluoro-2-(phenylcarbamoyl)anilino]-1-oxopropan-2-yl]carbamate Chemical compound BrC=1C(=C(C=CC=1F)NC([C@H](C)NC(OC(C)(C)C)=O)=O)C(NC1=CC=CC=C1)=O QMBFNSLJIANSKV-LBPRGKRZSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- QOQOMTMEZDJHNF-AWEZNQCLSA-N tert-butyl n-[(2s)-4-[3-chloro-2-(phenylcarbamoyl)phenyl]-3-oxobutan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H](C)C(=O)CC1=CC=CC(Cl)=C1C(=O)NC1=CC=CC=C1 QOQOMTMEZDJHNF-AWEZNQCLSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 125000001583 thiepanyl group Chemical group 0.000 description 2
- 125000002053 thietanyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 125000005503 thioxanyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 1
- DGIGGVANZFKXLS-KGLIPLIRSA-N (2s,4r)-1-[(2-methylpropan-2-yl)oxycarbonyl]-4-phenylmethoxypyrrolidine-2-carboxylic acid Chemical compound C1[C@@H](C(O)=O)N(C(=O)OC(C)(C)C)C[C@@H]1OCC1=CC=CC=C1 DGIGGVANZFKXLS-KGLIPLIRSA-N 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- XHTYQFMRBQUCPX-UHFFFAOYSA-N 1,1,3,3-tetramethoxypropane Chemical compound COC(OC)CC(OC)OC XHTYQFMRBQUCPX-UHFFFAOYSA-N 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- XBYRMPXUBGMOJC-UHFFFAOYSA-N 1,2-dihydropyrazol-3-one Chemical compound OC=1C=CNN=1 XBYRMPXUBGMOJC-UHFFFAOYSA-N 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- ZRHUHDUEXWHZMA-UHFFFAOYSA-N 1,4-dihydropyrazol-5-one Chemical compound O=C1CC=NN1 ZRHUHDUEXWHZMA-UHFFFAOYSA-N 0.000 description 1
- VSTXCZGEEVFJES-UHFFFAOYSA-N 1-cycloundecyl-1,5-diazacycloundec-5-ene Chemical compound C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 VSTXCZGEEVFJES-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- ICFGFAUMBISMLR-UHFFFAOYSA-N 1h-pyrazole-5-carbaldehyde Chemical compound O=CC=1C=CNN=1 ICFGFAUMBISMLR-UHFFFAOYSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-RALIUCGRSA-N 2,3,4,5,6-pentadeuterioaniline Chemical compound [2H]C1=C([2H])C([2H])=C(N)C([2H])=C1[2H] PAYRUJLWNCNPSJ-RALIUCGRSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- XUMALORDVCFWKV-IBGZPJMESA-N 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C[C@H](NC(=O)C1=C2N=CC=CN2N=C1N)C1=CC2=CC=CC(C#CC3=CN(C)N=C3)=C2C(=O)N1C1=CC=CC=C1 XUMALORDVCFWKV-IBGZPJMESA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- KQRCBMPPEPNNDS-UHFFFAOYSA-N 2-bromo-3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1Br KQRCBMPPEPNNDS-UHFFFAOYSA-N 0.000 description 1
- BMXJCILXNYCNJM-UHFFFAOYSA-N 2-bromo-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1CCC2=NC(Br)=CN21 BMXJCILXNYCNJM-UHFFFAOYSA-N 0.000 description 1
- JBKINHFZTVLNEM-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCBr JBKINHFZTVLNEM-UHFFFAOYSA-N 0.000 description 1
- LSPBZWVHXNOSFJ-UHFFFAOYSA-N 2-chloro-3-fluoro-6-methylbenzoic acid Chemical compound CC1=CC=C(F)C(Cl)=C1C(O)=O LSPBZWVHXNOSFJ-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- LPCQBTAOTIZGAE-UHFFFAOYSA-N 2h-pyrimidine-1-carboxamide Chemical compound NC(=O)N1CN=CC=C1 LPCQBTAOTIZGAE-UHFFFAOYSA-N 0.000 description 1
- CRDDRQWHQLBWAN-UHFFFAOYSA-N 3-(cyclopenten-1-yl)-6-pyridin-4-ylpyrazolo[1,5-a]pyrimidine Chemical compound C1CCC=C1C1=C2N=CC(C=3C=CN=CC=3)=CN2N=C1 CRDDRQWHQLBWAN-UHFFFAOYSA-N 0.000 description 1
- NEOIOGUWEUTYIH-UHFFFAOYSA-N 3-azabicyclo[3.2.0]heptane Chemical compound C1NCC2CCC21 NEOIOGUWEUTYIH-UHFFFAOYSA-N 0.000 description 1
- ASLSBGAOXZIHHP-UHFFFAOYSA-N 3-bromo-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole Chemical compound C1CCC2=C(Br)C=NN21 ASLSBGAOXZIHHP-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- ROADCYAOHVSOLQ-UHFFFAOYSA-N 3-oxetanone Chemical compound O=C1COC1 ROADCYAOHVSOLQ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 1
- WVGCPEDBFHEHEZ-UHFFFAOYSA-N 4-bromo-1h-pyrazole Chemical compound BrC=1C=NNC=1 WVGCPEDBFHEHEZ-UHFFFAOYSA-N 0.000 description 1
- BSDGZUDFPKIYQG-UHFFFAOYSA-N 4-bromopyridine Chemical compound BrC1=CC=NC=C1 BSDGZUDFPKIYQG-UHFFFAOYSA-N 0.000 description 1
- CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 1
- YTKATZJRHFWHBB-UHFFFAOYSA-N 4-ethenyloxetan-2-one Chemical compound C=CC1CC(=O)O1 YTKATZJRHFWHBB-UHFFFAOYSA-N 0.000 description 1
- MDQZVJSUBKPTHG-UHFFFAOYSA-N 4-ethyloxolan-2-one Chemical compound CCC1COC(=O)C1 MDQZVJSUBKPTHG-UHFFFAOYSA-N 0.000 description 1
- LLNQWPTUJJYTTE-UHFFFAOYSA-N 4-iodopyrazole Chemical compound IC=1C=NNC=1 LLNQWPTUJJYTTE-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- PQRBAZCVIZIHPD-UHFFFAOYSA-N 5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-2-ylmethanol Chemical compound C1CCN2N=C(CO)C=C21 PQRBAZCVIZIHPD-UHFFFAOYSA-N 0.000 description 1
- QGFYFOHMBDMGBZ-UHFFFAOYSA-N 5-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol Chemical compound C1=C(O)C(CN(CC)CC)=CC=C1NC1=CC=NC2=CC(Cl)=CC=C12 QGFYFOHMBDMGBZ-UHFFFAOYSA-N 0.000 description 1
- TZARUEALSRVVHC-UHFFFAOYSA-N 5-bromo-1-methylpyrazole Chemical compound CN1N=CC=C1Br TZARUEALSRVVHC-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108010059108 CD18 Antigens Proteins 0.000 description 1
- LWECGERCMMIKPX-INIZCTEOSA-N C[C@H](N)C1=CC2=CC=CC(C#CC3=CN(C)N=C3)=C2C(=O)N1C1=CC=CC=C1 Chemical compound C[C@H](N)C1=CC2=CC=CC(C#CC3=CN(C)N=C3)=C2C(=O)N1C1=CC=CC=C1 LWECGERCMMIKPX-INIZCTEOSA-N 0.000 description 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091007962 Class I PI3K catalytic Proteins 0.000 description 1
- 108091007958 Class I PI3Ks Proteins 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102100024025 Heparanase Human genes 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101710181812 Methionine aminopeptidase Proteins 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- DWGXTJWYCGSSSP-UHFFFAOYSA-N NC1=NN2C=CC=NC2=C1C(=O)ON1C(=O)CCC1=O Chemical compound NC1=NN2C=CC=NC2=C1C(=O)ON1C(=O)CCC1=O DWGXTJWYCGSSSP-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical group [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 229950010482 alpelisib Drugs 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- QYCSNMDOZNUZIT-UHFFFAOYSA-N benzhydrylidenehydrazine Chemical compound C=1C=CC=CC=1C(=NN)C1=CC=CC=C1 QYCSNMDOZNUZIT-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- RXGDWZCMJCMFNW-UHFFFAOYSA-N bicyclo[3.2.0]heptan-3-one Chemical compound C1C(=O)CC2CCC21 RXGDWZCMJCMFNW-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- ZDWYFWIBTZJGOR-UHFFFAOYSA-N bis(trimethylsilyl)acetylene Chemical compound C[Si](C)(C)C#C[Si](C)(C)C ZDWYFWIBTZJGOR-UHFFFAOYSA-N 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- GCSVCUMDOQKEMT-UHFFFAOYSA-N butan-1-amine;hydrofluoride Chemical compound [H+].[F-].CCCCN GCSVCUMDOQKEMT-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- UHKPOGGUWJGGID-UHFFFAOYSA-N carbonic acid;cesium Chemical compound [Cs].OC(O)=O UHKPOGGUWJGGID-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002559 chemokine receptor antagonist Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229950002550 copanlisib Drugs 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- MRKZAZMYXYSBDG-UHFFFAOYSA-N cyclopentyl propanoate Chemical compound CCC(=O)OC1CCCC1 MRKZAZMYXYSBDG-UHFFFAOYSA-N 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 125000005345 deuteroalkyl group Chemical group 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229950004949 duvelisib Drugs 0.000 description 1
- 229940125021 eganelisib Drugs 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- UKRYTIBFBUCJGB-UHFFFAOYSA-N ethyl 2-amino-5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate Chemical compound CCOC(=O)C1=C2N=C(Cl)C=CN2N=C1N UKRYTIBFBUCJGB-UHFFFAOYSA-N 0.000 description 1
- DSHWMBCJDOGPTB-UHFFFAOYSA-N ethyl 2-ethoxy-2-iminoacetate Chemical compound CCOC(=N)C(=O)OCC DSHWMBCJDOGPTB-UHFFFAOYSA-N 0.000 description 1
- MGGGSJRWNQFCLE-UHFFFAOYSA-N ethyl 5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxylate Chemical compound C1CCN2N=C(C(=O)OCC)C=C21 MGGGSJRWNQFCLE-UHFFFAOYSA-N 0.000 description 1
- FGCPAXRNQIOISG-UHFFFAOYSA-N ethyl 5-oxo-1,2-dihydropyrazole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(O)NN=1 FGCPAXRNQIOISG-UHFFFAOYSA-N 0.000 description 1
- JEMAMNBFHPIPCR-UHFFFAOYSA-N ethyl pyrazolo[1,5-a]pyrimidine-3-carboxylate Chemical compound C1=CC=NC2=C(C(=O)OCC)C=NN21 JEMAMNBFHPIPCR-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010037536 heparanase Proteins 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000006197 histone deacetylation Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical group 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229960003445 idelalisib Drugs 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N itaconic acid Chemical compound OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 238000003674 kinase activity assay Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- LROBJRRFCPYLIT-UHFFFAOYSA-M magnesium;ethyne;bromide Chemical compound [Mg+2].[Br-].[C-]#C LROBJRRFCPYLIT-UHFFFAOYSA-M 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- JFZRRXGXEHUJCI-UHFFFAOYSA-N methyl 1-methyl-5-oxopyrrolidine-3-carboxylate Chemical compound COC(=O)C1CN(C)C(=O)C1 JFZRRXGXEHUJCI-UHFFFAOYSA-N 0.000 description 1
- IYAQFZAPKKWPNU-UHFFFAOYSA-N methyl 2-methyl-5-oxo-1h-pyrazole-3-carboxylate Chemical compound COC(=O)C1=CC(=O)NN1C IYAQFZAPKKWPNU-UHFFFAOYSA-N 0.000 description 1
- SRXOJMOGPYFZKC-UHFFFAOYSA-N methyl 4-chloro-4-oxobutanoate Chemical compound COC(=O)CCC(Cl)=O SRXOJMOGPYFZKC-UHFFFAOYSA-N 0.000 description 1
- GRFNBEZIAWKNCO-UHFFFAOYSA-N mhp Natural products OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229960002259 nedocromil sodium Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- SJECIYLGISUNRO-UHFFFAOYSA-N o-diphenylphosphorylhydroxylamine Chemical compound C=1C=CC=CC=1P(=O)(ON)C1=CC=CC=C1 SJECIYLGISUNRO-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical group OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Chemical group 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 229940124654 piqray Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- SXYFKXOFMCIXQW-UHFFFAOYSA-N propanedioyl dichloride Chemical compound ClC(=O)CC(Cl)=O SXYFKXOFMCIXQW-UHFFFAOYSA-N 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- JVOGPCAZHXALIS-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine-3-carboxamide Chemical compound C1=CC=CC2=C(C(=O)N)C=NN21 JVOGPCAZHXALIS-UHFFFAOYSA-N 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- AQIDWPCFDNAMQW-UHFFFAOYSA-N pyridin-3-ol Chemical compound OC1=C=NC=C[CH]1 AQIDWPCFDNAMQW-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- JVQOZRRUGOADSU-UHFFFAOYSA-N tert-butyl 3-formylazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(C=O)C1 JVQOZRRUGOADSU-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000006223 tetrahydrofuranylmethyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- BUGOPWGPQGYYGR-UHFFFAOYSA-N thiane 1,1-dioxide Chemical compound O=S1(=O)CCCCC1 BUGOPWGPQGYYGR-UHFFFAOYSA-N 0.000 description 1
- 150000004912 thiazepines Chemical class 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- INQOMBQAUSQDDS-FIBGUPNXSA-N trideuterio(iodo)methane Chemical compound [2H]C([2H])([2H])I INQOMBQAUSQDDS-FIBGUPNXSA-N 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229940095188 zydelig Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention belongs to the field of medicine, and in particular relates to a new class of isoquinolinone and quinazolinone compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds, and the use of said compounds and their pharmaceutical combinations Use of the substance in the preparation of medicines for preventing, treating, treating, and/or alleviating PI3-kinase abnormality-related diseases, disorders, and/or conditions.
- the phosphoinositide 3-kinase (PI3K) pathway is an intracellular signaling pathway with regulatory roles in cell survival, proliferation and differentiation.
- the phosphoinositide 3-kinase (PI3K) enzyme family is a central regulator of growth, proliferation, migration and metabolism in many cells and tissues.
- PI3Ks are lipid kinases that generate the lipid second messenger phosphatidylinositol-3,4,5-triphosphate (PIP3), which is used downstream of cell surface receptors to regulate growth, metabolism, survival and differentiation.
- PIP3 is produced by four distinct class I PI3K catalytic isoforms, grouped into two groups: class IA (p110 ⁇ , p110 ⁇ , and p110 ⁇ ) and class IB (p110 ⁇ ).
- Class I PI3Ks are constitutively associated with regulatory subunits, the main difference between class IA and class IB PI3Ks is that they are associated with unique regulatory subunits.
- Class IA PI3Ks (PI3K ⁇ , PI3K ⁇ , and PI3K ⁇ ) are heterodimers composed of the catalytic subunit p110 (p110 ⁇ , p110 ⁇ , and p110 ⁇ , respectively) and the regulatory subunit p85 (e.g., p85 ⁇ , p85 ⁇ , p55 ⁇ , p55 ⁇ , and p50 ⁇ ) Complex). These signaling responses are often transmitted through receptor tyrosine kinases (RTKs).
- RTKs receptor tyrosine kinases
- GPCRs G protein-coupled receptors
- PI3K/mTOR pathway In normal cells, the PI3K/mTOR pathway has regulatory roles in cell survival, proliferation and differentiation. However, aberrant activation of this pathway has been linked to a variety of human diseases, including cancer, immunodeficiency, inflammation and developmental disorders.
- Various inhibitors targeting key nodes within the PI3K pathway are in various stages of clinical development for the treatment of various human diseases. (“Small-molecule inhibitors of the PI3K signaling network.” Future MedChem. 2011, 3(5), 549-565).
- the expression patterns of two isoforms of PI3K ⁇ and PI3K ⁇ are ubiquitous, while two isoforms of PI3K ⁇ and PI3K ⁇ are mainly expressed in leukocytes.
- the relatively restricted expression pattern of PI3K ⁇ and PI3K ⁇ suggests an important role for these two isoforms in the adaptive and innate immune system (J. Med. Chem. 2012, 55(20), 8559–8581).
- PI3K ⁇ isoforms are associated with angiogenesis and glucose homeostasis.
- the PI3K/mTOR pathway is frequently dysregulated in cancer, often because of activating mutations or amplification of PIK3CA.
- Gain-of-function mutations in PIK3CA (the gene encoding the PI3K p110 ⁇ catalytic subunit) are among the most common somatic alterations in solid tumors.
- PI3K ⁇ is predominantly expressed in cells of the hematopoietic lineage and is activated by cytokine receptors, antigen receptors, growth factor receptors, and costimulatory receptors. PI3K ⁇ is important in the development and activation of T and B cells. Blockade of PI3K ⁇ signaling increases gene instability. Gain-of-function (GOF) mutations in PI3K ⁇ lead to a range of developmental and functional defects in B and T cells, thereby compromising host defense. Loss-of-function (LOF) mutations lead to more severe B-cell lymphopenia and agammaglobulinemia but not T-cell senescence.
- GAF Gain-of-function
- the class IB PI3K catalytic subunit p110 ⁇ is a master regulator of immune cell function, and p110 ⁇ plays a key role in immune signaling.
- p110 ⁇ is a key factor in inflammatory diseases and has been identified as a therapeutic target in cancer due to its immunomodulatory effects.
- PI3K ⁇ plays an important role in the regulation of myeloid (macrophages, mast cells, neutrophils) and lymphoid (T cells, B cells, and natural killer cells)-derived immune cells. It regulates immune cell chemotaxis, cytokine release and production of reactive oxygen species.
- PI3K ⁇ The ability of PI3K ⁇ to mediate a variety of immune cell functions is controlled by its activation downstream of numerous cell surface receptors, including G protein-coupled receptors (GPCRs), IgE/antigen receptors, receptor tyrosine kinases (RTKs) and Toll-like receptors (TLRs).
- GPCRs G protein-coupled receptors
- IgE/antigen receptors IgE/antigen receptors
- RTKs receptor tyrosine kinases
- TLRs Toll-like receptors
- genetic or pharmacological deletion of PI3K ⁇ is protective against a variety of inflammatory diseases, including cardiovascular disease, arthritis, lupus, asthma, lung inflammation and fibrosis, and metabolic syndrome.
- PI3K ⁇ is also a driver of pancreatic ductal adenocarcinoma progression through immunomodulatory effects.
- the PI3K pathway has been the focus of drug development research over the past two decades.
- the PI3K ⁇ inhibitor idelalisib Zydelig; Gilead Sciences
- the pan-class I PI3K inhibitor copanlisib (Aliqopa; Bayer) was approved in 2017, and the dual PI3K ⁇ /PI3K ⁇ inhibitor duvelisib (Copiktra; Verastem, now Secura Bio) was approved in 2018 for the same indication.
- PI3K ⁇ inhibitor alpelisib (Piqray; Novartis) was the first and only FDA-approved drug in May 2019 in combination with the estrogen receptor (ER) down-regulator fulvestrant for the treatment of advanced PIK3CA-mutant HER2/ER+ metastases.
- PI3K ⁇ inhibitors in breast cancer were the first and only FDA-approved drug in May 2019 in combination with the estrogen receptor (ER) down-regulator fulvestrant for the treatment of advanced PIK3CA-mutant HER2/ER+ metastases.
- preferred compounds should bind potently to PI3K receptors while exhibiting little affinity for other receptors and exhibit functional activity as agonists.
- the compound should be fully absorbed by the gastrointestinal tract, stable in metabolism and have good pharmacokinetic properties. They freely cross the blood-brain barrier when targeting receptors in the central nervous system and should not cross the blood-brain barrier when selectively targeting receptors in the peripheral nervous system. They should be non-toxic and show few side effects.
- the ideal drug candidate should be in a stable, non-hygroscopic and easily formulated physical form.
- Compounds of the invention exhibit specific levels of selectivity against different paralogs of PI3K alpha, beta, gamma and delta. In particular, a certain level of selectivity against PI3K ⁇ was shown.
- the present invention provides a class of compounds capable of inhibiting, regulating and/or modulating the activity of PI3-kinase for treating and/or preventing diseases, disorders, and/or conditions related to PI3-kinase abnormality.
- the compound of the present invention has better pharmacological activity, specifically, the compound of the present invention shows excellent inhibitory activity to PI3-kinase, and has high selectivity to PI3K ⁇ , and liver microsomes are stable It has obvious advantages in sex, and has good pharmacokinetic properties and higher bioavailability. Therefore, the compounds of the present invention have very good development prospects.
- Stereoisomers refer to compounds that have the same chemical structure, but differ in the way the atoms or groups are arranged in space. Stereoisomers include enantiomers, diastereomers, conformers (rotamers), geometric isomers (cis/trans) isomers, atropisomers, etc. .
- the compounds of the present invention can be optionally substituted by one or more substituents, such as the general formula compounds of the present invention, or as specific examples, subclasses in the embodiments, and included in the present invention a class of compounds.
- substituted means that one or more hydrogen atoms in a given structure, whether attached to C or N or otherwise, have been replaced by a particular substituent.
- substituents Unless otherwise indicated, an optional substituent group may be substituted at each substitutable position of the group. When more than one position in a given formula can be substituted by one or more substituents selected from a particular group, then the substituents can be substituted at each position the same or differently.
- C 1 -C 6 alkyl specifically refers to independently disclosed methyl, ethyl, C 3 alkyl, C 4 alkyl, C 5 alkyl and C 6 alkyl.
- alkyl or "alkyl group” used in the present invention means a saturated linear or branched monovalent hydrocarbon group containing 1 to 20 carbon atoms, wherein the alkyl group can be optionally substituted by one or more of the substituents described herein. Unless otherwise specified, an alkyl group contains 1-20 carbon atoms. In one embodiment, the alkyl group contains 1-12 carbon atoms; in another embodiment, the alkyl group contains 1-6 carbon atoms; in yet another embodiment, the alkyl group contains 1 - 4 carbon atoms; in yet another embodiment, the alkyl group contains 1-3 carbon atoms. The alkyl group may be optionally substituted with one or more substituents described herein.
- alkyl groups include, but are not limited to, methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), n-propyl (n-Pr, -CH 2 CH 2 CH 3 ), isopropyl (i-Pr, -CH(CH 3 ) 2 ), n-butyl (n-Bu, -CH 2 CH 2 CH 2 CH 3 ), isobutyl (i-Bu, -CH 2 CH (CH 3 ) 2 ), sec-butyl (s-Bu, -CH(CH 3 )CH 2 CH 3 ), tert-butyl (t-Bu, -C(CH 3 ) 3 ), n-pentyl (-CH 2CH 2 CH 2 CH 2 CH 3 ), 2-pentyl (-CH(CH 3 )CH 2 CH 2 CH 3 ), 3-pentyl (-CH(CH 2 CH 3 ) 2 ), 2-methyl -2-butyl (-C(CH 3 )
- alkenyl means a linear or branched monovalent hydrocarbon group containing 2-12 carbon atoms, wherein there is at least one site of unsaturation, that is, there is a carbon-carbon sp2 double bond, which includes “cis” and " The positioning of "anti”, or the positioning of "E” and "Z".
- an alkenyl group contains 2-8 carbon atoms; in another embodiment, an alkenyl group contains 2-6 carbon atoms; in yet another embodiment, an alkenyl group contains 2 - 4 carbon atoms.
- the alkenyl group can be optionally substituted with one or more substituents described herein.
- alkynyl means a linear or branched monovalent hydrocarbon group containing 2-12 carbon atoms, in which there is at least one site of unsaturation, ie, a carbon-carbon sp triple bond.
- the alkynyl group contains 2-8 carbon atoms; in another embodiment, the alkynyl group contains 2-6 carbon atoms; in yet another embodiment, the alkynyl group contains 2 - 4 carbon atoms.
- alkynyl groups include, but are not limited to, ethynyl (-C ⁇ CH), propargyl ( -CH2C ⁇ CH ), 1-propynyl (-C ⁇ C- CH3 ), and the like .
- the alkynyl group can be optionally substituted with one or more substituents described herein.
- alkoxy denotes an alkyl group attached to the rest of the molecule through an oxygen atom, wherein the alkyl group has the meaning set forth herein. Unless specified otherwise, the alkoxy groups contain 1-12 carbon atoms. In one embodiment, the alkoxy group contains 1-6 carbon atoms; in another embodiment, the alkoxy group contains 1-4 carbon atoms; in yet another embodiment, the alkoxy group Groups contain 1-3 carbon atoms. The alkoxy groups may be optionally substituted with one or more substituents described herein.
- alkoxy groups include, but are not limited to, methoxy (MeO, -OCH 3 ), ethoxy (EtO, -OCH 2 CH 3 ), 1-propoxy (n-PrO, n- Propoxy, -OCH 2 CH 2 CH 3 ), 2-propoxy (i-PrO, i-propoxy, -OCH(CH 3 ) 2 ), 1-butoxy (n-BuO, n- Butoxy, -OCH 2 CH 2 CH 2 CH 3 ), 2-methyl-l-propoxy (i-BuO, i-butoxy, -OCH 2 CH(CH 3 ) 2 ), 2-butane Oxygen (s-BuO, s-butoxy, -OCH(CH 3 )CH 2 CH 3 ), 2-methyl-2-propoxy (t-BuO, t-butoxy, -OC(CH 3 ) 3 ), 1-pentyloxy (n-pentyloxy, -OCH 2 CH 2 CH 2 CH 2 CH 3 ),
- haloalkyl or “haloalkoxy” means that an alkyl or alkoxy group is substituted with one or more halogen atoms, examples of which include, but are not limited to, trifluoromethyl (-CF 3 ), Trifluoromethoxy (-OCF 3 ), difluoroethyl (-CH 2 CHF 2 , -CF 2 CH 3 , -CHFCH 2 F), trifluoroethyl (-CH 2 CF 3 , -CF 2 CH 2 F, -CFHCHF 2 ), -CF(CH 3 ) 2 and so on.
- halogen atoms examples of which include, but are not limited to, trifluoromethyl (-CF 3 ), Trifluoromethoxy (-OCF 3 ), difluoroethyl (-CH 2 CHF 2 , -CF 2 CH 3 , -CHFCH 2 F), trifluoroethyl (-CH 2 CF 3 , -CF 2 CH 2 F,
- deuteroalkyl means an alkyl , alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl groups are substituted with one or more D atoms, examples of which include, but are not limited to, monodeuteromethyl (-CH 2 D), Dideuteromethyl (-CHD 2 ), Trideuteromethyl (-CD 3 ), One Deuteriomethoxy (-OCH 2 D), Dideuuteriomethoxy (-OCHD 2 ), Trideuteriomethoxyl (-OCD 3 ), Dideuuterioethyl (-CH 2 CHD 2 , -CD 2 CH 3 , -CHDCH 2 D), Pentadeuterioethyl (-CD 2 CD 3 ), Deuterium Substituted cyclopropy
- deuterium (D)-containing group means that one or more H atoms on the group or part of the group described in the present invention are replaced by D, but do not include a single D group, such groups include , but not limited to, C 1-6 deuterated alkyl, C 3-8 deuterated cycloalkyl, C 2-9 deuterated heterocyclyl, C 6-10 deuterated aryl, C 1-9 deuterated hetero Aryl, etc., each of which has the definition described in the present invention, wherein each of the groups is independently and optionally replaced by one or more of H, D, F, Cl, Br, I, -OH, -CN, -NO 2 , -NR e R f , C 1-6 alkyl and C 1-6 deuterated alkyl are substituted, wherein both R e and R f have the definitions described in the present invention.
- hydroxyalkyl or "hydroxy-substituted alkyl” and “hydroxyalkoxy” or “hydroxy-substituted alkoxy” denote respectively an alkyl or alkoxy group, as the case may be, surrounded by one or more hydroxy groups, where “hydroxyalkyl” and “hydroxyalkyl” are used interchangeably, such examples include, but are not limited to, hydroxymethyl (-CH 2 OH), 2-hydroxyethyl ( -CH 2 CH 2 OH), 1-hydroxyethyl (-CH(OH)CH 3 ), 2-hydroxypropan-2-yl (-COH(CH 3 ) 2 ), 2-hydroxy-2-methylpropane (-CH 2 COH(CH 3 ) 2 ), 3-hydroxypropyl (-CH 2 CH 2 CH 2 OH), 2-hydroxypropyl (-CH 2 CH(OH)CH 3 ), 2-hydroxy- 2-methylpropyl (-CH 2 CH(OH)(CH 3 )CH 3 ), hydroxymethoxy (-OCH 2 OH) and
- cyano-substituted alkyl or “cyanoalkyl” includes C 1-10 straight or branched chain alkyl groups substituted with one or more cyano groups.
- cyanoalkyl is C 1-6 "lower cyanoalkyl” substituted with one or more cyano groups, and in other embodiments, cyanoalkyl is C 1-4 "lower cyanoalkyl” substituted with one or more cyano groups, examples of which include, but are not limited to, CNCH 2 -, CNCH 2 CH 2 -, CNCH 2 CH 2 CH 2 -, CNCH 2 CHCNCH 2 -, etc.
- alkylamino includes “N-alkylamino” and "N,N-dialkylamino", wherein the amino groups are each independently substituted with one or two alkyl groups.
- alkylamino is a lower alkylamino group with one or two C 1-6 alkyl groups attached to a nitrogen atom.
- the alkylamino is a C 1-3 lower alkylamino group.
- Suitable alkylamino groups may be mono- or di-alkylamino, examples of which include, but are not limited to, N-methylamino, N-ethylamino, N,N-dimethylamino, N,N- -Diethylamino and the like.
- aminoalkyl includes C 1-10 straight or branched chain alkyl groups substituted with one or more amino groups.
- the aminoalkyl group is a C 1-6 "lower aminoalkyl” substituted with one or more amino groups, and in other embodiments, the aminoalkyl group is substituted with one or more C 1-4 "lower aminoalkyl” substituted with an amino group, examples of which include, but are not limited to, aminomethyl, aminoethyl, aminopropyl, aminobutyl and aminohexyl.
- cycloalkyl denotes a monovalent or polyvalent saturated monocyclic, bicyclic or tricyclic ring system containing 3 to 12 carbon atoms.
- Bicyclic cycloalkyls include spirobicycloalkyls, fused bicycloalkyls and bridged bicycloalkyls.
- cycloalkyl groups contain 3-12 carbon atoms; in other embodiments, cycloalkyl groups contain 3-10 carbon atoms; in other embodiments, cycloalkyl groups contain 3-8 carbon atoms Atom; In other embodiments, cycloalkyl contains 3-7 carbon atoms; In other embodiments, cycloalkyl contains 3-6 carbon atoms; Still in some embodiments, cycloalkyl is C 7 -C 12 cycloalkyl, which includes C 7 -C 12 monocycloalkyl, C 7 -C 12 bicycloalkyl (such as C 7 -C 12 spirobicycloalkyl, C 7 -C 12 fused bicycloalkyl and C 7 -C 12 bridged bicycloalkyl) or C 7 -C 12 tricycloalkyl.
- the cycloalkyl groups can be independently unsubstituted or substituted with one or more substituents described herein.
- the term "monocyclic cycloalkyl” or “monocycloalkyl” refers to a cycloalkyl group of a monocyclic ring system, wherein said cycloalkyl group has the definition as previously stated, and said monocyclic cycloalkyl group can be independently Unsubstituted or substituted with one or more substituents described herein.
- cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopentyl-1-enyl, 1-cyclopentyl-2-enyl, 1-cyclo Pentyl-3-enyl, cyclohexyl, 1-cyclohexyl-1-enyl, 1-cyclohexyl-2-enyl, 1-cyclohexyl-3-enyl, cyclohexadienyl, cycloheptyl , cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, etc.
- cycloalkylalkyl includes cycloalkyl substituted alkyl groups.
- a cycloalkylalkyl group refers to a "lower cycloalkylalkyl” group, ie, a cycloalkyl group attached to a C 1-6 alkyl group.
- a cycloalkylalkyl group refers to a C 1-3 alkyl-containing "phenylalkylene.” Specific examples thereof include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclopentylethyl, cyclohexylethyl, and the like.
- the cycloalkyl group on the cycloalkylalkyl group may be further substituted with one or more substituents described herein.
- heterocyclyl and “heterocycle” are used interchangeably herein, and both refer to monovalent or multivalent, saturated or partially unsaturated, non-aromatic monocyclic, Bicyclic or tricyclic ring systems wherein at least one ring atom is selected from nitrogen, oxygen and sulfur atoms.
- a heterocyclyl or heterocycle contains 4-12 ring atoms.
- a heterocyclyl or heterocycle contains 5-12 ring atoms.
- a heterocyclyl or heterocycle contains 4-8 ring atoms.
- a heterocyclyl or heterocycle contains 3-10 ring atoms.
- a heterocyclyl or heterocycle contains 3-8 ring atoms. In some embodiments, a heterocyclyl or heterocycle contains 3-6 ring atoms. In some embodiments, a heterocyclyl or heterocycle contains 4-7 ring atoms.
- the heterocyclic group includes a saturated heterocyclic group (heterocycloalkyl group) and a partially unsaturated heterocyclic group.
- Said heterocyclyl has one or more points of attachment to the rest of the molecule.
- heterocyclic groups include, but are not limited to: oxiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrrolinyl, pyrazolinyl, pyrazole Alkyl, imidazolinyl, imidazolidinyl, tetrahydrofuryl, dihydrofuryl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxolyl, dithiocyclopentyl, tetrahydropyranyl , Dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, piperidiny
- Examples of oxidized sulfur atoms in heterocyclic groups include, but are not limited to, sulfolane, 1,1-dioxothiomorpholinyl.
- Said heterocyclyl groups may be optionally substituted with one or more substituents described herein.
- the heterocyclic group is a heterocyclic group composed of 4-7 atoms, which refers to a monovalent or polyvalent, saturated or partially unsaturated non-aromatic monocyclic ring containing 4-7 ring atoms Or bicyclic, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms.
- Ring sulfur atoms can optionally be oxidized to S-oxides.
- Ring nitrogen atoms can optionally be oxidized to N-oxygen compounds.
- the 4-7 atom heterocyclic group has one or more points of attachment to the rest of the molecule.
- examples of monocyclic heterocyclic groups composed of 4-7 atoms include, but are not limited to: azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrrolinyl , pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, tetrahydrofuryl, dihydrofuryl, tetrahydrothiophenyl, dihydrothiophenyl, tetrahydropyranyl, dihydropyranyl, 2H -pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, dioxanyl, dithianyl, thioxanyl, 1,2-oxaziny
- heterocyclylalkyl includes heterocyclyl substituted alkyl, wherein both heterocyclyl and alkyl have the meanings described herein, such examples include, but are not limited to tetrahydrofuranylmethyl, pyrrole- 2-ylmethyl, morpholin-4-ylethyl, piperazin-4-ylethyl, piperidin-4-ylethyl and the like.
- aryl denotes monocyclic, bicyclic and tricyclic carbocyclic ring systems containing 6-14 ring atoms, or 6-12 ring atoms, or 6-10 ring atoms, wherein at least one ring system is aromatic family in which each ring system contains rings of 3-7 atoms and has one or more points of attachment to the rest of the molecule.
- aryl is used interchangeably with the term “aromatic ring”. Examples of aryl groups may include phenyl, naphthyl and anthracenyl. The aryl groups may be independently optionally substituted with one or more substituents described herein.
- arylalkyl or “aralkyl” includes aryl-substituted alkyl groups.
- an arylalkyl group refers to a "lower arylalkyl” group, ie, an aryl group attached to a C 1-6 alkyl group.
- an arylalkyl group refers to a C 1-3 alkyl-containing "phenylalkylene.” Specific examples thereof include, but are not limited to, benzyl, diphenylmethyl, phenethyl and the like.
- the aryl group on the arylalkyl group may be further substituted with one or more substituents described herein.
- heteroaryl denotes monocyclic, bicyclic and tricyclic ring systems containing 5-12 ring atoms, or 5-10 ring atoms, or 5-6 ring atoms, wherein all rings are aromatic, and At least one aromatic ring contains one or more heteroatoms, wherein each ring system contains rings of 5-7 atoms and has one or more points of attachment to the rest of the molecule.
- heteroaryl may be used interchangeably with the terms “heteroaryl” or “heteroaromatic”.
- the heteroaryl group is a 5-12 atom heteroaryl group comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N.
- the heteroaryl group is a 5-10 atom heteroaryl group comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N. In another embodiment, the heteroaryl group is a 5-6 atom heteroaryl group comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N.
- the heteroaryl group is optionally substituted with one or more substituents described herein.
- heteroaryl groups include, but are not limited to, 2-furyl, 3-furyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl , 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2- Pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (such as 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (such as 5-tetrazolyl), triazolyl (such as 2-triazolyl and 5-triazolyl), 2-thienyl, 3-thienyl, pyrazolyl (such as 2-thi
- heteroarylalkyl means that an alkyl group is substituted by one or more heteroaryl groups, wherein both heteroaryl and alkyl groups have the meanings described herein, examples of which include, but are not Limited to, pyridine-2-methyl, imidazol-2-methyl, furan-2-ethyl, indole-3-methyl and the like.
- halogen refers to F, Cl, Br or I.
- connection points in the ring system connected to the rest of the molecule there are two connection points in the ring system connected to the rest of the molecule, as shown in formula (a1), which means that either the E end or the E' end is connected to the rest of the molecule, that is, the two ends of the Connection methods can be interchanged.
- substituents are bonded to a central ring to form a ring system (shown below) meaning that substituents can be substituted at any substitutable position on either ring.
- formula b represents that any position that may be substituted on ring A or ring B can be substituted, such as formula c, d, e, f, g, h, i, j, k, l, m, n, o, Shown by p, q, etc.
- the "pharmaceutically acceptable salt” used in the present invention refers to organic and inorganic salts of the compounds of the present invention.
- Pharmaceutically acceptable salts are well known in the art, as described in the literature: SM Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66: 1-19.
- Pharmaceutically acceptable non-toxic acid salts include, but are not limited to, inorganic acid salts formed by reaction with amino groups such as hydrochloride, hydrobromide, phosphate, sulfate, perchlorate, and organic acid salts such as acetate, oxalate, maleate, tartrate, citrate, succinate, malonate, or other methods such as ion exchange methods recorded in books and literature these salts.
- salts include adipate, alginate, ascorbate, aspartate, besylate, benzoate, bisulfate, borate, butyrate, camphorate Salt, camphorsulfonate, cyclopentylpropionate, digluconate, lauryl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate Salt, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, Malate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, palmitate, pamoate, pectate, persulfate, 3 - Phenylpropionate,
- Salts obtained with appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 alkyl) 4 salts.
- the present invention also contemplates the quaternary ammonium salts of any compound containing an N group.
- Water-soluble or oil-soluble or dispersed products can be obtained by quaternization.
- Alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
- Pharmaceutically acceptable salts further include suitable, non-toxic ammonium, quaternary ammonium salts and amine cations formed as counterions, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, C 1 -8 sulfonates and aromatic sulfonates.
- a “solvate” of the present invention refers to an association of one or more solvent molecules with a compound of the present invention.
- Solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethylsulfoxide, ethyl acetate, acetic acid, and aminoethanol.
- hydrate refers to an association of solvent molecules with water.
- the invention discloses a novel class of pyrimidine amine compounds, which can be used as inhibitors of PI3-kinase activity, especially PI3K- ⁇ activity, for preventing, treating, treating, and/or alleviating PI3-kinase abnormality-related diseases, disorders, and/or conditions such as respiratory disease, viral infection, non-viral respiratory infection, allergic disease, autoimmune disease, inflammatory disease, cardiovascular disease, hematologic malignancy, neurodegenerative disease, pancreatitis, multiorgan failure, Kidney disease, platelet aggregation, cancer, sperm motility, transplant rejection, graft rejection, lung damage or pain, etc.
- PI3-kinase abnormality-related diseases, disorders, and/or conditions such as respiratory disease, viral infection, non-viral respiratory infection, allergic disease, autoimmune disease, inflammatory disease, cardiovascular disease, hematologic malignancy, neurodegenerative disease, pancreatitis, multiorgan failure, Kidney disease, platelet aggregation, cancer, sperm mot
- the compound of the present invention Compared with existing similar compounds, the compound of the present invention has better pharmacological activity, specifically, the compound of the present invention shows excellent inhibitory activity to PI3-kinase and has high selectivity to PI3K ⁇ , and pharmacokinetic Significant advantages in academics. Therefore, the compounds of the present invention have very good development prospects.
- the compounds disclosed in the present invention can show strong inhibitory activity on PI3-kinase, especially PI3K- ⁇ .
- the present invention provides a kind of isoquinolones and quinazolinones compound, it has the structure shown in formula (I):
- X is -C(R c )-, or N;
- Z 1 and Z 2 are each independently -C(R 4d )- or N;
- R a , R b and R c are each independently H, D, F, Cl, C 1-3 alkyl, C 1-6 deuterated alkyl, C 1-3 alkoxy, C 1-3 haloalkyl , C 1-3 hydroxyalkyl, C 1-3 aminoalkyl, C 1-3 cyanoalkyl, C 1-6 deuterated alkoxy, C 1-6 haloalkyl substituted by 1 to 5 deuteriums , a C 1-6 hydroxyalkyl group substituted by 1 to 5 deuteriums, a C 3-8 cycloalkyl group substituted by 1 to 5 deuteriums, or a C 1-9 heteroaryl group substituted by 1 to 5 deuteriums;
- R 3 is H, D, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkane Base, C 3-8 deuterated cycloalkyl, C 2-9 heterocyclyl, C 6-10 aryl, or C 1-9 heteroaryl; wherein R 3 is optionally replaced by 0, 1, 2, 3 , 4 or 5 R 6 substitutions;
- R e , R f , R 7 and R 7a are independently H, D, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl C 1-6 alkyl, C 2-9 heterocyclyl, C 2-9 heterocyclyl C 1-6 alkyl , C 6-10 aryl, C 6-10 aryl C 1-6 alkyl, C 1-9 heteroaryl, or C 1-9 heteroaryl C 1-6 alkyl; wherein each C 1 -6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl, C 1-6 alkyl, C 2-9 heterocyclyl, C 2-9 heterocyclyl C 1-6 alkyl, C 6-12 aryl, C 6-12 aryl C 1-6 alkyl, C
- n 0, 1, 2, or 3;
- the present invention provides a kind of isoquinolones and quinazolinones compound, it has the structure shown in formula (Ib):
- X is -C(R c )-, or N;
- Z 1 and Z 2 are each independently -C(R 4d )- or N;
- R a , R b and R c are each independently H, D, F, Cl, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 alkoxy, C 1-3 haloalkyl , C 1-3 hydroxyalkyl, C 1-3 aminoalkyl, or C 1-3 cyanoalkyl;
- R 3 is H, D, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkane Base, C 3-8 deuterated cycloalkyl, C 2-9 heterocyclyl, C 6-10 aryl, or C 1-9 heteroaryl; wherein R 3 is optionally replaced by 0, 1, 2, 3 , 4 or 5 R 6 substitutions;
- R e , R f , R 7 and R 7a are independently H, D, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl C 1-6 alkyl, C 2-9 heterocyclyl, C 2-9 heterocyclyl C 1-6 alkyl , C 6-10 aryl, C 6-10 aryl C 1-6 alkyl, C 1-9 heteroaryl, or C 1-9 heteroaryl C 1-6 alkyl; wherein each C 1 -6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl, C 1-6 alkyl, C 2-9 heterocyclyl, C 2-9 heterocyclyl C 1-6 alkyl, C 6-12 aryl, C 6-12 aryl C 1-6 alkyl, C
- n 0, 1, 2, or 3;
- the compound shown in formula (I) has the structure shown in formula (Ia):
- R is phenyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, thiazolyl, imidazolyl, oxazolyl, thiazolyl oxadiazolyl,
- Y 1 is O, S, or -NH-;
- Y 6 is O, or -NH-
- t3 and t4 are each independently 1, 2, 3 or 4;
- R is optionally substituted by 0, 1, 2, 3 or 4 R 5 ;
- R 1 is When, wherein R 1 is optionally substituted by 0, 1, 2, 3 or 4 R 5 , then at least one of each R 2 , R 4a , R 4b and R 4c is independently F, Cl, -CN, C 1-3 alkoxy, C 1-3 deuterated alkyl, C 1-3 deuterated alkoxy, C 1-3 haloalkyl substituted by 1 to 5 deuteriums, substituted by 1 to 5 deuteriums C 1-3 hydroxyalkyl, C 3-6 cycloalkyl substituted by 1 to 5 deuteriums, or C 1-9 heteroaryl substituted by 1 to 5 deuteriums; 2) when R 1 is phenyl, Pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, thiazolyl, imidazolyl, oxazolyl, thiadiazolyl, , wherein R 1 is optionally substituted by 0, 1, 2, 3 or 4 R
- R is phenyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, thiazolyl, imidazolyl, oxazolyl, thiazolyl oxadiazolyl,
- Y 1 is O, S, or -NH-;
- Y 6 is O, or -NH-
- t3 and t4 are each independently 1, 2, 3 or 4;
- R is optionally substituted by 0, 1, 2, 3 or 4 R 5 ;
- R 1 is , then at least one of R 2 , R 4a , R 4b and R 4c is independently F, Cl, or a deuterium-containing group; 2) when R 1 is phenyl, pyridyl, pyridazinyl, pyridyl Azinyl, pyrimidinyl, triazinyl, thiazolyl, imidazolyl, oxazolyl, thiadiazolyl, , then at least one of R a , R b , R c , R 2 , R 3 , R 4a , R 4b , R 4c and R 4d is independently D (deuterium), or a deuterium-containing group.
- R 4a , R 4b , R 4c and R 4d are each independently H, F, Cl, D, -CN, -OCH 3 , - OCH2CH3 ,
- X is -C(R c )-, or N;
- W is C 3-10 cycloalkyl, C 2-9 heterocyclyl, C 6-10 aryl, or C 1-9 heteroaryl; wherein W is optionally replaced by 0, 1, 2, 3 or 4 R 4 replaces;
- R a , R b and R c are each independently H, D, F, Cl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 alkoxy, C 1-6 haloalkyl , C 1-6 hydroxyalkyl, C 1-6 aminoalkyl, or C 1-6 cyanoalkyl;
- Y 2 and Y 3 are each independently -(CH 2 ) t1 -, -(CH 2 ) t1 -L-, -(CH 2 ) t1 -L-(CH 2 ) t2 -, O, or -NH- ;
- Y 5 is -CH-, or N
- Y 6 is O, or -NH-
- Y 7 is O, or -NH-
- each occurrence of t1, t2 and t3 is independently 1, 2, 3 or 4;
- R is optionally substituted by 0, 1, 2, 3 or 4 R 5 ;
- R 3 is H, D, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkane Base, C 3-8 deuterated cycloalkyl, C 2-9 heterocyclyl, C 6-10 aryl, or C 1-9 heteroaryl; wherein R 3 is optionally replaced by 0, 1, 2, 3 , 4 or 5 R 6 substitutions;
- R e , R f , R 7 and R 7a are independently H, D, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl C 1-6 alkyl, C 2-9 heterocyclyl, C 2-9 heterocyclyl C 1-6 alkyl , C 6-10 aryl, C 6-10 aryl C 1-6 alkyl, C 1-9 heteroaryl, or C 1-9 heteroaryl C 1-6 alkyl; wherein each C 1 -6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl, C 1-6 alkyl, C 2-9 heterocyclyl, C 2-9 heterocyclyl C 1-6 alkyl, C 6-12 aryl, C 6-12 aryl C 1-6 alkyl, C
- n 0, 1, 2, or 3.
- W is C 3-8 cycloalkyl, C 3-8 heterocyclyl
- Z 1 , Z 2 and Z 3 are each independently -CH-, or N;
- W is optionally substituted by 0, 1, 2, 3 or 4 R 4 .
- the compound shown in formula (II) has the structure shown in formula (IIa):
- n 0, 1, 2 or 3.
- R is wherein R 1 is optionally substituted by 0, 1, 2, 3 or 4 R 5 .
- R 3 is cyclopropyl, pyridyl, or phenyl; wherein R 3 is optionally replaced by 0, 1, 2, 3, 4 or 5 independently selected from H, D, F, Cl, Br, I, -OH, -CN, -NO 2 , -NR e R f , C 1-3 alkyl, C 1 -3 alkoxy, C 1-3 deuterated alkyl and C 1-3 haloalkyl group substitution.
- R a , R b and R c are each independently H, D, F, -CN, -NO 2 , -NR e R f , methyl, ethyl, isopropyl, -CD 3 , -CHD 2 , -CH 2 D, methoxy, ethoxy, halomethyl, haloethyl, or -CH 2 CH 2 OH.
- R e , R f , R 7 and R 7a are independently H , D, C 1-4 alkyl, C 1-4 deuterated alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl C 1-4 alkyl, C 3-6 heterocyclyl, C 3-6 heterocyclyl C 1-4 alkyl, C 6-10 aryl, C 6-10 aryl C 1-4 alkyl, C 1 -9 heteroaryl, or C 1-9 heteroaryl C 1-4 alkyl; wherein each C 1-4 alkyl, C 1-4 deuterated alkyl, C 1-4 haloalkyl, C 1 -4 hydroxyalkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl C 1-4 alkyl, C 3-6 heterocycly
- R e , R f , R 7 and R 7a are independently H , D, C 1-2 alkyl, C 1-2 deuterated alkyl, C 1-2 haloalkyl, phenyl, or cyclopropyl.
- the compound is a compound having one of the following structures:
- the compound is a compound having one of the following structures:
- the compounds disclosed herein may contain asymmetric or chiral centers and thus exist in different stereoisomeric forms.
- the present invention intends to make all stereoisomeric forms of compounds shown in formula (I), (Ia), (Ib), (II) or (IIa), including but not limited to diastereoisomers, enantiomers isomers, atropisomers and geometric (or conformational) isomers, as well as mixtures thereof, such as racemic mixtures, form part of the present invention.
- stereochemistry of any particular chiral atom when the stereochemistry of any particular chiral atom is not indicated, then all stereoisomers of the structure are contemplated and included in the present invention as disclosed compounds .
- stereochemistry is indicated by a solid wedge or a dashed line indicating a particular configuration, then the stereoisomers of that structure are identified and defined.
- the compound represented by formula (I), (Ia), (Ib), (II) or (IIa) may exist in the form of a salt.
- the salt refers to a pharmaceutically acceptable salt.
- pharmaceutically acceptable means that the substance or composition must be chemically and/or toxicologically compatible with the other ingredients comprising the formulation and/or with the mammal being treated therewith.
- the salt is not necessarily a pharmaceutically acceptable salt, but may be used for preparing and/or purifying the salt shown in formula (I), (Ia), (Ib), (II) or (IIa).
- the present invention relates to intermediates for the preparation of compounds represented by formula (I), (Ia), (Ib), (II) or (IIa).
- the present invention relates to methods for preparing, isolating and purifying compounds represented by formula (I), (Ia), (Ib), (II) or (IIa).
- the present invention provides a pharmaceutical composition comprising a compound of the present invention.
- the pharmaceutical composition of the present invention further includes a pharmaceutically acceptable adjuvant, diluent or carrier, or a combination thereof.
- the pharmaceutical composition may be in liquid, solid, semi-solid, gel or spray form.
- compositions described herein further comprise additional therapeutic agents.
- the present invention relates to a method for preventing, treating, treating, and/or alleviating PI3-kinase-mediated diseases, disorders, and and/or a condition, or use in a drug that inhibits PI3-kinase activity.
- the PI3-kinase-mediated disease, disorder, and/or condition is selected from respiratory disease, viral infection, non-viral respiratory infection, allergic disease, autoimmune disease, inflammatory disease, cardiovascular disease , hematological malignancy, neurodegenerative disease, pancreatitis, multiple organ failure, renal disease, platelet aggregation, cancer, sperm motility, transplant rejection, graft rejection, lung injury, or pain.
- the PI3-kinase-mediated disease, disorder, and/or condition is selected from asthma, chronic obstructive pulmonary disease (COPD), viral respiratory infection, exacerbation of viral respiratory disease, aspergillosis, leishmaniasis disease, allergic rhinitis, allergic dermatitis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, thrombosis, atherosclerosis, hematological malignancy, neurodegenerative disease, pancreatitis, multiple organ failure, kidney disease , platelet aggregation, cancer, sperm motility, transplant rejection, graft rejection, lung injury, pain associated with rheumatoid arthritis or osteoarthritis, back pain, systemic inflammatory pain, retrohepatic neuralgia, diabetic neuropathy , inflammatory neuropathic pain (trauma), trigeminal neuralgia or central pain.
- COPD chronic obstructive pulmonary disease
- viral respiratory infection exacerbation of viral
- the cancer is selected from acute myelogenous leukemia, myelodysplastic syndrome, myeloproliferative disorder, chronic myelogenous leukemia, T-cell acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, non-Hodgkin's lymphoma , B-cell lymphoma, solid tumor, or breast cancer.
- PI3-kinase is PI3K- ⁇ .
- the present invention provides a pharmaceutical composition, which comprises the compounds disclosed in the present invention, or the compounds listed in the examples, or their stereoisomers, tautomers, nitrogen oxides, solvates, metabolites or pharmaceutically an acceptable salt; and a pharmaceutically acceptable adjuvant, diluent, carrier, vehicle or a combination thereof.
- the amount of the compound in the pharmaceutical composition disclosed in the present invention refers to the amount that can effectively detect and inhibit the protein kinase in biological samples or patients.
- compositions of the invention may exist in free form for use in therapy or, if appropriate, as a pharmaceutically acceptable derivative thereof.
- pharmaceutically acceptable derivatives include pharmaceutically acceptable salts, esters, salts of these esters, or compounds that provide, directly or indirectly, the compounds of the present invention or their derivatives when administered to a patient in need thereof. Any additional adducts or derivatives of metabolites or residues.
- compositions provided by the present invention can be formulated with other active ingredients that do not impair the intended therapeutic effect, or with substances that supplement the intended effect.
- the compounds of the invention are inhibitors of kinase activity, especially inhibitors of PI3-kinase activity.
- Compounds that are PI3-kinase inhibitors are useful in the treatment of disorders in which the underlying pathology is attributable (at least in part) to inappropriate PI3-kinase activity, such as asthma, chronic obstructive pulmonary disease (COPD), viral infections, non-viral respiratory infections, Allergic disease, autoimmune disease, inflammatory disease, cardiovascular disease, hematologic malignancy, neurodegenerative disease, pancreatitis, multiorgan failure, renal disease, platelet aggregation, cancer, sperm motility, transplant rejection, graft rejection, Lung damage or pain, etc.
- COPD chronic obstructive pulmonary disease
- Inappropriate PI3-kinase activity refers to any PI3-kinase activity that deviates from the normal PI3-kinase activity expected in a particular patient.
- An inappropriate PI3-kinase can take the form, for example, of an abnormal increase in activity, or an aberration or malfunction of the PI3-kinase. These inappropriate activities may result, for example, from overexpression or mutations of protein kinases that result in inappropriate or uncontrolled activation. Accordingly, in another aspect, the invention relates to methods of treating said diseases or conditions.
- Such diseases or conditions include, but are not limited to, respiratory diseases, including asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis (IPF); viral infections, including viral respiratory infections and viral respiratory disease exacerbations, Examples include asthma and COPD; nonviral respiratory infections, including aspergillosis and leishmaniasis; allergic diseases, including allergic rhinitis and atopic dermatitis; autoimmune diseases, including rheumatoid arthritis and multiple sclerosis; Inflammatory disease, including inflammatory bowel disease; cardiovascular disease, including thrombosis and atherosclerosis; hematological malignancies; neurodegenerative disease; pancreatitis; multiple organ failure; renal disease; platelet aggregation; cancer; sperm motility ; transplant rejection; graft rejection; lung injury; and pain, including pain associated with rheumatoid arthritis or osteoarthritis, back pain, systemic inflammatory pain, retrohepatic neuralgia, diabetic neuropathy, inflammatory
- such disorders include, respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD); allergic diseases, including allergic rhinitis and atopic dermatitis; autoimmune diseases, including rheumatoid arthritis inflammation and multiple sclerosis; inflammatory diseases, including inflammatory bowel disease; cardiovascular disease, including thrombosis and atherosclerosis; hematological malignancies; neurodegenerative diseases; pancreatitis; multiple organ failure; renal disease; platelets Aggregation; cancer; sperm motility; transplant rejection; Neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia, and central pain.
- respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD); allergic diseases, including allergic rhinitis and atopic dermatitis; autoimmune diseases, including rheumatoid arthritis inflammation and multiple sclerosis; inflammatory diseases, including inflammatory bowel disease; cardiovascular disease, including thrombosis and atherosclerosis; hematological malignancies;
- the cancer is selected from acute myelogenous leukemia, myelodysplastic syndrome, myeloproliferative disorder, chronic myelogenous leukemia, T-cell acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, non-Hodgkin Gold lymphoma, B-cell lymphoma, solid tumor, or breast cancer.
- the treatment method of the present invention comprises administering a safe and effective amount of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof to a patient in need.
- Various embodiments of the present invention include methods for treating any of the disorders or diseases mentioned in the present invention by administering a safe and effective amount of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof to a patient in need.
- the compounds of the present invention may be administered as the sole active agent, or may be administered in combination with other therapeutic agents, including other compounds that have the same or similar therapeutic activity and are determined to be safe and effective for such combination administration.
- the present invention provides a method for treating, preventing or ameliorating a disease or condition, comprising administering a safe and effective amount of a combination drug comprising a compound disclosed in the present invention and one or more therapeutically active agents.
- the combination comprises one or two other therapeutic agents.
- therapeutic agents include, but are not limited to: anti-cancer agents, including chemotherapeutics and anti-proliferative agents; anti-inflammatory agents; and immunomodulators or immunosuppressants.
- the invention provides a product comprising a compound of the invention and at least one other therapeutic agent, prepared as a combination for simultaneous, separate or sequential administration in therapy.
- the treatment is for a disease or condition mediated by the activity of one or more protein kinases, such as PI3k-kinase.
- Products provided by combination preparations include compositions comprising a compound disclosed herein and an additional therapeutic agent in the same pharmaceutical composition, or in different forms, eg, a kit.
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound disclosed herein and one or more additional therapeutic agents.
- the pharmaceutical composition may comprise pharmaceutically acceptable excipients as described above.
- the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which comprises a compound disclosed herein.
- the kit includes means for individually maintaining the compositions, such as containers, divided bottles, or divided foil boxes.
- An example of such a kit is a blister pack, which is commonly used for packaging tablets, capsules and the like.
- Compounds disclosed herein may be administered as the sole active ingredient or co-administered with other therapeutic agents, eg, as adjuvants.
- such additional therapeutic agents include, for example, immunosuppressants, immunomodulators, or other anti-inflammatory agents for the treatment or prevention of acute or chronic rejection of allograft or xenograft, or inflammatory, or autoimmune disease drugs, or chemotherapeutic agents, such as antiproliferative agents for malignant tumor cells.
- the compound represented by the formula (I) of the present invention is used together with other immunosuppressants/immunomodulators, anti-inflammatory agents, chemotherapeutic agents or anti-infective agents, wherein immunosuppressants/immunomodulators, anti-inflammatory agents, chemotherapeutic agents Or the dose of anti-infective agent co-administration depends on the type of co-administration, whether it is a steroid compound or a calcineurin inhibitor, and the specific drug being used for treatment and the treatment situation.
- anti-inflammatory agents include non-steroidal anti-inflammatory drugs (NSAIDs).
- NSAIDs include cromolyn sodium, nedocromil sodium, phosphodiesterase (PDE) inhibitors (such as theophylline, PDE4 inhibitors, or mixed PDE3/PDE4 inhibitors), leukotriene antagonists , leukotriene synthesis inhibitors (eg, montelukast), iNOS inhibitors, trypsin and elastase inhibitors, beta-2 integrin antagonists, and adenosine receptor agonists or antagonists (eg, adenosine 2 ⁇ receptor agonists), cytokine antagonists (such as chemokine receptor antagonists, including CCR3 antagonists), cytokine synthesis inhibitors, or 5-lipoxygenase inhibitors.
- PDE phosphodiesterase
- the compounds of formula (I) may also advantageously be used in combination with other compounds, or in combination with other therapeutic agents, especially antiproliferative agents.
- antiproliferative agents include, but are not limited to, aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule activating agents; alkylating agents; histone deacetylation Enzyme inhibitors; compounds that induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; antineoplastic antimetabolites; platinum compounds; compounds that target/reduce protein or lipid kinase activity and other anti- Angiogenic compounds; Compounds that target, decrease, or inhibit protein or lipid phosphatase activity; Gonadorelin-like agonists; Antiandrogens; Methionine aminopeptidase inhibitors; Bisphosphonates; Biological response modifiers ; antiproliferative antibodies; heparanase inhibitors
- Combination means a fixed combination in single dosage unit form or a kit of parts for combined administration wherein the compound disclosed herein and the combination partner may be administered independently at the same time or may be administered separately at intervals , especially to make joint partners exhibit cooperation, such as synergy.
- co-administration or “combination administration” and the like as used herein are intended to encompass the administration of selected combination partners to a single individual (e.g. patient) in need thereof, and are intended to include where the substances do not necessarily have to be administered by the same route of administration or Concomitant treatment regimens.
- the methods of treatment disclosed herein comprise administering to a patient in need thereof a safe and effective amount of a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
- Various embodiments disclosed herein include methods of treating the diseases or conditions described herein by administering to a patient in need thereof a safe and effective amount of a compound disclosed herein or a pharmaceutical composition comprising a compound disclosed herein.
- a compound disclosed herein or a pharmaceutical composition comprising a compound disclosed herein may be administered at one time, or several times at different time intervals within a specified period of time according to a dosing regimen. For example, once, twice, three or four times per day. In one embodiment, the administration is once daily. In yet another embodiment, the administration is twice daily. Administration can be until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for compounds disclosed herein or pharmaceutical compositions comprising compounds disclosed herein depend on the pharmacokinetic properties of the compound, such as dilution, distribution and half-life, which can be determined by the skilled artisan.
- suitable dosing regimens for compounds disclosed herein or pharmaceutical compositions comprising compounds disclosed herein including the duration for which such regimens are carried out, depend on the disease being treated, the severity of the disease being treated, the age and Physical condition, medical history of the patient being treated, nature of concurrent therapy, desired therapeutic effect, etc., are factors within the knowledge and experience of the skilled person. It will also be understood by those skilled in the art that the response of an individual patient to the dosing regimen, or as the individual patient's needs change over time, may require adjustment of the appropriate dosing regimen.
- the pharmaceutical composition or combination/combination of the present invention may be about 1-1000 mg active ingredient, or about 1-500 mg, or about 1-250 mg, or about 1-150 mg, or about 0.5-100 mg, or about 1 - a unit dose of 50 mg of active ingredient.
- Therapeutically effective dosages of the compounds, pharmaceutical compositions or combinations thereof depend on the individual's species, body weight, age and individual disease, disorder or condition or severity being treated. A physician, clinician or veterinarian of ordinary skill in the art can readily determine the effective amount of each active ingredient for preventing, treating or inhibiting the progression of a disease or condition.
- the dosage properties cited above have been demonstrated in in vitro and in vivo experiments using mammals, eg, mice, rats, dogs, monkeys, or isolated organs, tissues and specimens thereof, advantageously.
- the compounds of the present invention can be administered in vitro in the form of solutions, eg, aqueous solutions, and in vivo in the form of suspensions or aqueous solutions enterally, parenterally and preferably intravenously.
- a therapeutically effective amount in vivo ranges depending on the route of administration and is between about 0.01-500 mg/kg, or between about 1-100 mg/kg.
- a compound disclosed herein may be administered simultaneously with, prior to, or subsequent to, one or more other therapeutic agents.
- the compound of the present invention can be administered separately with other therapeutic agents through the same or different routes of administration, or in the form of the same pharmaceutical composition.
- the compounds of the present invention can be prepared by the methods described in the present invention, unless there are further instructions, wherein the substituents are defined as formula (I), (Ia), (Ib), (II) or (IIa) shown.
- the following reaction schemes and examples serve to further illustrate the present invention.
- Anhydrous THF, dioxane, DCM, toluene and DMF were purchased from commercial suppliers such as Energy chemical company and Aldrich chemical company.
- EtOAc, PE, CH3CN , NMP and DMSO were all treated with anhydrous Na2SO4 before use.
- reaction vials were fitted with suitable rubber stoppers, and the substrate was introduced by syringe. Glassware is dried.
- the chromatographic column is a silica gel column.
- Silica gel 300-400 mesh was purchased from Qingdao Ocean Chemical Factory.
- 1 H NMR spectra and 13 C/2D data were collected on a Bruker Avance III 400 MHz.
- 1 H NMR spectrum uses CDC1 3 , DMSO-d 6 , CD 3 OD or acetone-d 6 as the solvent (in ppm), and TMS (0 ppm) or chloroform (7.26 ppm) as the reference standard.
- LC/MS was performed on an Agilent 1260 (binary pump/DAD detector) coupled to an Agilent 6120/6125 mass spectrometer.
- MeCN aqueous solution (0.1% HCOOH), flow rate: 20ml/min, 50ml/min, column 30x250mm, 10 ⁇ m; wavelength: 210-400nm. Samples were injected into DMSO (+ optional formic acid and water) and eluted with a linear gradient from 10% to 95% MeCN over 10 minutes.
- Aqueous solution of MeCN (0.1% trifluoroacetic acid), flow rate: 20ml/min, 50ml/min, column 30x250mm, 10 ⁇ m; wavelength: 210-400nm. Samples were injected into DMSO (+ optional formic acid and water) and eluted with a linear gradient from 10% to 95% MeCN over 10 minutes.
- Aqueous solution of MeCN (0.1% NH 3 -H 2 O/10 mM NH 4 AC), flow rate: 20 ml/min, 50 ml/min, column 30x250 mm, 10 ⁇ m; wavelength: 210-400 nm.
- Samples were injected into DMSO (+ optional formic acid and water) and eluted with a linear gradient from 10% to 95% MeCN over 10 minutes.
- R 1 , R 2 , R 3 , R 4a , R 4b , R 4c , R a , R b , X, Z 1 , Z 2 , W and n all have the definitions as described in the present invention.
- the compound of the present invention having the structure shown in formula (6) can be prepared by the general synthesis method described in Synthesis Scheme 1, and the specific steps can be referred to the examples.
- compound (1) can be synthesized by purchasing commercial reagents or referring to literature (WO2016149160A1).
- Compound (1) is coupled with a terminal alkyne substituted with R 1 under the catalysis of a suitable palladium salt or copper salt to obtain compound (3).
- the Boc protecting group is removed under acidic conditions to obtain the derivative of compound (4).
- Compound (4) and compound (5) react under suitable alkaline conditions or in the presence of a condensing agent to obtain the target kinase inhibitor (6).
- the compound of the present invention having the structure shown in formula (8) can be prepared by the general synthesis method described in Synthesis Scheme 2, and the specific steps can be referred to the examples.
- Synthesis Scheme 2 amine derivatives (4) and carboxylic acid derivatives (7) are condensed in the presence of a suitable condensing agent to obtain the target kinase inhibitor (8).
- the alkyne derivatives with the structure shown in formula (2) can be prepared by the general synthesis method described in Fragment Synthesis Scheme 1, and the specific steps can be referred to the examples.
- compound (2-a) is under suitable basic conditions (such as potassium carbonate, cesium carbonate and potassium phosphate, etc.), and trimethylethynyl silicon is under the catalysis of suitable palladium salt and copper salt Coupling affords compound (2-b).
- suitable basic conditions such as potassium carbonate, cesium carbonate and potassium phosphate, etc.
- trimethylethynyl silicon is under the catalysis of suitable palladium salt and copper salt Coupling affords compound (2-b).
- the TMS protecting group was removed by TBAF to obtain the alkyne derivative (2).
- R substituted aldehyde derivatives (2-c) under suitable basic conditions, and (1-diazo-2-oxopropyl)phosphonic acid dimethyl ester at low temperature reaction to give alkyne Class derivatives (2).
- the carboxylic acid derivative having the structure shown in formula (5) can be prepared by the general synthesis method described in Fragment Synthesis Scheme 2, and the specific steps can be referred to the examples.
- Synthesis Scheme 3 compound (5-a) is deethylated under suitable basic conditions to obtain carboxylic acid derivative (5-b).
- Compound (5-b) and compound (4) are condensed in the presence of a condensing agent (such as EDCI or HATU) to obtain the target kinase inhibitor (6).
- a condensing agent such as EDCI or HATU
- Compound (5-b) and N-hydroxysuccinimide are condensed in the presence of a condensing agent to obtain compound (5-c). Under suitable alkaline conditions, compound (5-c) reacts with compound (4) to obtain target kinase inhibitor (6).
- deuterium-containing synthetic building blocks used in the synthesis of compounds of the present invention include commercial reagents, and can be synthesized through references (such as WO2017161116A1), specifically including but not limited to the following structures:
- EDCI (279.8 mg, 1.46 mmol) and 1-hydroxypyrrolidine-2,5-dione (168 mg, 1.46 mmol) were added to 2-aminopyrazolo[1,5-a]pyrimidine-3-carboxylic acid ( 200 mg, 1.12 mmol) in DMF (10 mL), the mixture was stirred at room temperature for 16 h. After the reaction was completed, it was diluted with water (30ml), and extracted three times with ethyl acetate (30mL x 3).
- Step 8) (S)-2-amino-N-(1-(8-((5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)ethynyl)- 1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl)pyrazolo[1,5-a]pyrimidine-5,7-D2-3-carboxamide
- the mixture was cooled to room temperature, concentrated under reduced pressure to remove solvent, and diluted with dichloromethane (30 mL). The mixture was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure.
- Step 5 3-((1S)-1-aminoethyl)-8-(2-(1-((2,4-dimethoxyphenyl)methyl)-5-oxopyrrolidine-3 -yl)ethynyl)-2-phenylisoquinolin-1-one
- the mixture was heated at 80°C for 5 hours, and after cooling down to room temperature, the mixture was concentrated under reduced pressure, the residue was diluted with ethyl acetate (30 mL), the mixture was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate Concentrate under reduced pressure.
- n-butyllithium (2.4N n-hexane solution, 5.9mL, 14.3mmol) dropwise to a solution of diisopropylamine (1.38g, 13.6mmol) in tetrahydrofuran (30mL). Stir for 1 hour. Then the mixture was cooled to -70°C, a solution of 4-(1-bromovinyl)dihydrofuran-2(3H)-one (650mg, 3.4mmol) in tetrahydrofuran (3mL) was added, stirred at -10°C for 2 hours .
- Step 3 3-((S)-1-aminoethyl)-8-((5-oxotetrahydrofuran-3-yl)ethynyl)-2-phenylisoquinolin-1(2H)-one
- Step 2) 3-((S)-1-aminoethyl)-8-((3-hydroxyoxetan-3-yl)ethynyl)-2-phenylnaphthalene-1(2H)-one
- Step 2 Tert-butyl (S)-(4-(3-chloro-2-(cyclopropylcarbamoyl)phenyl)-3-oxobutan-2-yl)carbamate
- Step 6 (S)-2-amino-N-(1-(8-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)ethynyl)-1- Oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
- Step 2) 7-Bromo-2,3-dihydropyrazolo[5,1-b]oxazole
- Step 6) (S)-2-amino-N-(1-(8-((2,3-dihydropyrazolo[5,1-b]oxazol-7-yl)ethynyl)-1- Oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
- Step 2 (S)-2-amino-N-(1-(5-((5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)ethynyl)- 4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
- Step 2) (S)-2-amino-N-(1-(7-fluoro-8-((1-methyl-1H-pyrazol-4-yl)ethynyl)-1-oxo-2- Phenyl-1,2-dihydroisoquinolin-3-yl))ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
- Step 6) (S)-2-amino-N-(1-(8-((6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3- Base) ethynyl)-1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
- the mixture was diluted with DCM (50 mL) and washed with brine (30 mL x 2). The layers were separated, and the organic phase was washed with brine (50 mL), dried over anhydrous Na 2 SO 4 , filtered, and concentrated in vacuo.
- Step 7) (S)-2-amino-N-(1-(6-fluoro-5-((1-methyl-1H-pyrazol-4-yl)ethynyl)-4-oxo-3- Phenyl-3,4-dihydroquinazolin)-2-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
- Example 29 2-Amino-N-((1S)-1-(8-(2-(1-methyl-5-oxopyrrolidin-3-yl)ethynyl)-1-oxo-2 -phenylisoquinolin-3-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; and
- Example 30 6-(3-((S)-1-(2 -aminopyrazolo[1,5-a]pyrimidine-3-carboxamido)ethyl)-1-oxo-2-phenyl-1,2-dihydroisoquinolin-8-yl)-4 -Hydroxy-hex-5-ynoic acid methyl ester
- Step 3 3-((1S)-1-aminoethyl)-8-(2-(5-oxooxolan-2-yl)ethynyl)-2-phenylisoquinoline-1 - Ketone; 6-(3-((S)-1-aminoethyl)-1-oxo-2-phenyl-1,2-dihydroisoquinolin-8-yl)-4-hydroxy-hexyl -5-ynoic acid methyl ester
- Step 4) 2-amino-N-((1S)-1-(8-(2-(1-methyl-5-oxopyrrolidin-3-yl)ethynyl)-1-oxo-2- phenylisoquinolin-3-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 6-(3-((S)-1-(2-aminopyrazolo[ 1,5-a]pyrimidine-3-carboxamido)ethyl)-1-oxo-2-phenyl-1,2-dihydroisoquinolin-8-yl)-4-hydroxy-hexan-5 -Methyl alkynoate
- Step 2) 4-bromo-1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-pyrazole-5-carbaldehyde
- Step 7) (S)-2-amino-N-(1-(8-((6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine-3- Base) ethynyl)-1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
- Step 1) (S)-2-(1-aminoethyl)-5-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)ethynyl)-6- Fluoro-3-phenylquinazolin-4(3H)-one
- 6-ethynyl-2,3-dihydropyrazolo[5,1-b]oxazole (50mg, 0.14mmol) and 2-ethynyl-5H,6H-pyrazolo[3 ,2-b][1,3]oxazole (18.5 mg, 0.14 mmol) in acetonitrile (20 mL) was added Pd 2 (dba) 3 (32 mg, 0.034 mmol), X-phos (33 mg, 0.07 mmol) and K 3 PO 4 (88mg, 0.41mmol), the mixture was warmed up to 80°C and stirred for 4h. After cooling to room temperature, it was concentrated in vacuo.
- Step 2 (S)-2-amino-N-(1-(5-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)ethynyl)-6- Fluoro-4-oxo-3-phenyl)-3,4-dihydroquinazolin-2-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
- Step 9) 3-((S)-1-Aminoethyl)-8-(((R)-5-Hydroxy-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole- 3-yl)ethynyl)-2-phenylisoquinolin-1(2H)-one
- Step 2) (S)-tert-butyl(4-(3-chloro-4-fluoro-2-((phenyl-d5)carbamoyl)phenyl)-3-oxobutan-2-yl)carbamate ester
- Step 6 (S)-2-amino-N-(1-(7-fluoro-8-((1-methyl-1H-pyrazol-4-yl-5-d)ethynyl)-1-oxo Substitute-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
- nitric acid (4.1 g, 0.064 mol, 2.6 mL) was added dropwise to a solution of 2-chloro-6-methylbenzoic acid (10 g, 0.0586 mol) in sulfuric acid (100 mL), and the mixture was stirred for 30 minutes, then transferred To room temperature, stirred for 16h. The mixture was slowly poured into ice water (260 mL) and stirring was continued for 1 h. After filtration, the filter cake was washed with water (50 mL) and dried in vacuo to obtain 6-chloro-2-methyl-3-nitrobenzoic acid (12.5 g, yield 98%) as a white solid.
- LCMS MS (ESI) m/z 214.4 [MH] - .
- Step 8) (S)-2-Amino-N-(1-(5-fluoro-8-((1-(methyl-d3)-1H-pyrazol-4-yl)ethynyl)-1-oxo Substitute-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
- Step 2) (S)-2-Amino-5-(methoxy-d3)-N-(1-(8-((1-(methyl-d3)-1H-pyrazol-4-yl)acetylene Base)-1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
- Step 6 (S)-2-Amino-5-bromo-N-(1-(8-((1-(methyl-d3)-1H-pyrazol-4-yl)ethynyl)-1-oxo Substitute-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl)pyrazolo[1,5-a]pyridine-3-carboxamide
- Kinase Activity Assay The activity of the compounds of the present invention as PI3K and mTOR kinase inhibitors can be evaluated by the following assays.
- Kinase assays are performed by detecting myelin basic protein (MBP) incorporation of [gamma]-33P-ATP. Prepare 20 ⁇ g/mL of MBP (Sigma#M-1891) tris-buffered saline (TBS; 50 mM Tris pH 8.0, 138 mM NaCl, 2.7 mM KCl), and coat a high-binding white 384-well plate (Greiner ), 60 ⁇ L per well. Incubate at 4°C for 24 hours.
- MBP myelin basic protein
- kinase reactions were performed in a total volume of 34 ⁇ L of kinase buffer (5 mM Hepes pH 7.6, 15 mM NaCl, 0.01% bovine serum albumin (Sigma #I-5506), 10 mM MgCl 2 , 1 mM DTT, 0.02% TritonX-100).
- kinase buffer 5 mM Hepes pH 7.6, 15 mM NaCl, 0.01% bovine serum albumin (Sigma #I-5506), 10 mM MgCl 2 , 1 mM DTT, 0.02% TritonX-100.
- Compounds were dissolved in DMSO and added to the wells at a final concentration of 1% DMSO. Each data was measured twice, and the determination of each compound was carried out at least twice. For example, the final concentration of the enzyme is 10 nM or 20 nM.
- the reaction was started by adding unlabeled ATP (10 ⁇ M) and ⁇ -33P-labeled ATP (2 ⁇ 10 6 cpm per well, 3000Ci/mmole). The reaction was carried out with shaking at room temperature for 1 hour. The 384-well plate was washed with 7x PBS, and then 50 ⁇ L of scintillation fluid was added to each well. A Wallac Trilux meter can also be used.
- IC50 of inhibition and/or inhibition constant Ki can be obtained by the above test method.
- IC50 is defined as the concentration of compound that inhibits 50% of the enzyme activity under the assay conditions.
- Use a 1/2 log dilution to generate a curve containing 10 concentration points to estimate the IC50 value (for example, make a typical curve through the following compound concentrations: 10 ⁇ M, 3 ⁇ M, 1 ⁇ M, 0.3 ⁇ M, 0.1 ⁇ M, 0.03 ⁇ M, 0.01 ⁇ M, 0.003 ⁇ M, 0.001 ⁇ M and 0 ⁇ M).
- HTRF homogeneous time-resolved fluorescence
- the cellular activity of the compounds of the present invention as PI3K kinase inhibitors can be evaluated by the following tests.
- PI3K- ⁇ , ⁇ subtypes First the compounds were diluted to 5 mM from stock concentration with 100% DMSO. In the second step, 5 mM compound was used as the first point and diluted 10 points by 4 times with 100% DMSO. In the third step, it is diluted 250-fold with serum-free medium, and the concentration of DMSO at this time is 0.4%. Then transfer 50 ⁇ L of the compound that has been diluted with medium to a 50 ⁇ L cell plate.
- the concentration of DMSO is 0.2%, and the final concentration of the compound is 10000nM, 2500nM, 625nM, 156.25nM, 39.06nM, 9.77nM, 2.44nM, 0.61nM, 0.15nM, 0.04nM.
- PI3K-beta, delta isoforms Compounds were first diluted from stock concentration to 1.25 mM in 100% DMSO. In the second step, 1.25 mM compound was used as the first point and diluted 10 points by 4 times with 100% DMSO.
- the third step is to dilute 35.714 times with serum-free medium, then transfer 2.5 ⁇ L of the compound that has been diluted with the medium to a 30 ⁇ L cell plate, incubate in the incubator for 1 hour, and then add 2.5 ⁇ L anti-IgM at this time
- the concentration of DMSO was 0.2%, and the final concentrations of the compounds were 2500nM, 625nM, 156.25nM, 39.06nM, 9.77nM, 2.44nM, 0.61nM, 0.15nM, 0.04nM, 0.01nM.
- SKOV-3 cells were seeded into a 96-well plate of cell culture level at a density of 60,000 cells/50 ⁇ L/well, and the cell culture medium was RPMI-1640 without serum. Cultivated overnight in a 5% CO2 incubator at 37°C. Add 50 ⁇ L/well of the test compound to the cells and incubate for 60 minutes at 37°C in a 5% CO2 incubator with a final DMSO concentration of 0.2%. Aspirate the medium and add 50 ⁇ L of 1x lysis solution to each well. Shake at room temperature for 45 minutes.
- 786-O cells were seeded into a 96-well plate of cell culture level at a density of 30,000 cells/50 ⁇ L/well, and the cell culture medium was RPMI-1640 without serum. Cultured overnight in a 5% CO2 incubator at 37°C. Add 50 ⁇ L/well of the test compound to the cells and incubate for 60 minutes at 37°C in a 5% CO2 incubator with a final DMSO concentration of 0.2%. Aspirate the medium and add 50 ⁇ L of 1x lysis solution to each well. Shake at room temperature for 45 minutes. Transfer 16 ⁇ L of the lysate to a 384 plate, and add 4 ⁇ L of premixed antibody from Cisbio’s Phospho-AKT (Ser473) kit. Centrifuge at 1000rpm/min for one minute, incubate at 22°C for 4 hours and read with Envision (665nm/615nm).
- Raji cells were cultured in 96-well plates at 30 ⁇ L per well, 50,000 cells, and the cell culture medium was RPMI-1640 without serum. Cells were incubated overnight in a 5% CO2 incubator at 37°C. After 18 hours of serum-free starvation, 2.5 ⁇ L of compound (14X) was added to the cells and incubated for 60 minutes in the incubator. Then 2.5 ⁇ L (14X, diluted with serum medium) of anti-human IgM (Jackson Immuno Research) was added and placed in the incubator to stimulate for 30 minutes (final concentration was 10 ⁇ g/mL). Add 11.5 ⁇ L of 4x Lysis Buffer to each well. Shake at room temperature for 45 minutes.
- RAW264.7 cells were resuspended in serum-free DMEM medium, and 60,000 cells/45 ⁇ L of cell suspension were added to each well of a 96-well plate. Cells were incubated overnight in a 5% CO2, 37°C incubator. After 18 hours of serum-free starvation, 50 ⁇ L of the compound was added and incubated in the incubator for 60 minutes. Then, 5 ⁇ L of 25 nM C5a (R&D Systems, diluted with serum medium) was added to stimulate for 5 min. Aspirate the medium and add 50 ⁇ L of 1x Lysis Buffer to each well. Shake at room temperature for 45 minutes.
- the kinase test in the present invention is completed by BaoDuo Biotechnology (Jiangsu) Co., Ltd., and the test results are shown in Table 2, wherein, +: >500nM; ++: 100-500nM; +++: 50-100nM; ++++: ⁇ 50nM.
- test results show that the compound of the present invention has significant inhibitory activity on PI3K ⁇ , and has very obvious selectivity on other PI3K subtypes.
- the compound of the present invention has higher selectivity than the positive drug IPI-549.
- the metabolic stability of the compounds of the present invention as PI3K kinase inhibitors can be evaluated by the following assay.
- liver microsomal stability assay
- test compound was co-incubated with human liver microsomes, and NADPH was added to start the reaction. At 0, 5, 15, 30 and 60 minutes, 30 microliters were withdrawn and transferred to 300 microliters of acetonitrile containing an internal standard to stop the reaction. This was followed by vigorous vortexing for 1 minute and centrifugation at 4000 rpm for 15 minutes below 4°C. After protein precipitation, 100 microliters of the supernatant was taken out, diluted with 100 microliters of distilled water and analyzed by LC-MS/MS method. Calculate the intrinsic clearance rate in vitro according to the elimination half-life of the test compound in the incubation system. Verapamil was used as a control compound, and both were incubated in parallel for 5 minutes.
- the percent remaining (%Remaining) was calculated from the ratio of the peak area of the test compound in the non-zero time point sample to the zero time point sample.
- the elimination half-life (T 1/2 , min) and in vitro intrinsic clearance (C Lint , ⁇ L.min -1 .mg -1 ) of the test compound are obtained by the following equation:
- Table 3 shows the parameters related to the stability of human liver microsomes of the compounds of the examples of the present invention and IPI-549.
- Example 16 and Example 28 of the present invention when the hydrogen of the methyl group on pyrazole is replaced by deuterium, the stability of human liver microsomes is significantly improved; similarly, comparing Example 21 and Example 37 of the present invention, the After the hydrogen of the methyl group was replaced by deuterium, the stability of human liver microsomes was also significantly improved.
- PI3K kinase inhibitors The pharmacokinetic studies of the compounds of the present invention as PI3K kinase inhibitors can be evaluated by the following tests.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
Abstract
La présente invention concerne des composés isoquinolinone et quinazolinone représentés par la formule (I) ou (II), une composition pharmaceutique contenant les composés, et l'utilisation des composés et de la composition pharmaceutique de ceux-ci dans la préparation d'un médicament pour prévenir, traiter et/ou atténuer des maladies, troubles et/ou états médiés par la PI3-kinase, ou pour inhiber une activité PI3-kinase. Ces composés présentent une excellente activité inhibitrice et une excellente sélectivité vis-à-vis de la kinase pour une kinase cible, et ont de bonnes propriétés pharmacocinétiques et une plus grande biodisponibilité.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111145359 | 2021-09-28 | ||
CN202111145359.4 | 2021-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023051495A1 true WO2023051495A1 (fr) | 2023-04-06 |
Family
ID=85770085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/121567 WO2023051495A1 (fr) | 2021-09-28 | 2022-09-27 | Composés isoquinolinone et quinazolinone, et composition et utilisation de ceux-ci |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115873000A (fr) |
WO (1) | WO2023051495A1 (fr) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160122365A1 (en) * | 2014-10-03 | 2016-05-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN105793255A (zh) * | 2013-10-04 | 2016-07-20 | 无限药品股份有限公司 | 杂环化合物及其用途 |
US20190135833A1 (en) * | 2016-06-08 | 2019-05-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US20190202835A1 (en) * | 2016-03-17 | 2019-07-04 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
WO2019228404A1 (fr) * | 2018-05-31 | 2019-12-05 | 信达生物制药(苏州)有限公司 | Nouveau inhibiteur de phosphoïnositide 3-kinase et procédé de préparation et d'utilisation associé |
WO2021004421A1 (fr) * | 2019-07-08 | 2021-01-14 | 浙江海正药业股份有限公司 | Dérivé alcyne, son procédé de préparation et ses utilisations |
-
2022
- 2022-09-27 WO PCT/CN2022/121567 patent/WO2023051495A1/fr unknown
- 2022-09-27 CN CN202211183447.8A patent/CN115873000A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105793255A (zh) * | 2013-10-04 | 2016-07-20 | 无限药品股份有限公司 | 杂环化合物及其用途 |
US20160122365A1 (en) * | 2014-10-03 | 2016-05-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US20190202835A1 (en) * | 2016-03-17 | 2019-07-04 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
US20190135833A1 (en) * | 2016-06-08 | 2019-05-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2019228404A1 (fr) * | 2018-05-31 | 2019-12-05 | 信达生物制药(苏州)有限公司 | Nouveau inhibiteur de phosphoïnositide 3-kinase et procédé de préparation et d'utilisation associé |
WO2021004421A1 (fr) * | 2019-07-08 | 2021-01-14 | 浙江海正药业股份有限公司 | Dérivé alcyne, son procédé de préparation et ses utilisations |
Also Published As
Publication number | Publication date |
---|---|
CN115873000A (zh) | 2023-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI753892B (zh) | 作為tam抑制劑之吡咯并三嗪化合物 | |
US9533988B2 (en) | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | |
US10000507B2 (en) | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | |
JP2019081786A (ja) | Trkaキナーゼ阻害剤としてのn−ピロリジニル、n’−ピラゾリル尿素、チオ尿素、グアニジン、およびシアノグアニジン化合物 | |
WO2020239077A1 (fr) | Régulateur dérivé hétérocyclique contenant de l'azote, son procédé de préparation et son application | |
TWI537272B (zh) | 製備抗病毒治療用的吡唑並[1,5-a]嘧啶類之方法 | |
KR101837223B1 (ko) | 피리디논/피라지논, 그의 제조 방법 및 사용 방법 | |
WO2020108590A1 (fr) | Pyrimidine et dérivé hétérocycle pentagonal de nitrogène, leur procédé de préparation et applications médicales | |
WO2021143680A1 (fr) | Dérivé hétéroaryle, son procédé de préparation et son utilisation | |
TW201404779A (zh) | 新的雜芳基和雜環化合物、其組合物及方法 | |
TW201514145A (zh) | 作為btk抑制劑的初級甲醯胺 | |
KR20180051624A (ko) | 피라졸릴 치환된 헤테로아릴 및 의약으로서의 이의 용도 | |
TW202104223A (zh) | 磷脂醯肌醇3-激酶抑制劑 | |
BR112016025835B1 (pt) | Composto de pirrolopirimidina ou sal do mesmo, inibidor de nae, composição farmacêutica e agente antitumor | |
CN114340634A (zh) | 作为激酶抑制剂的杂环化合物 | |
WO2022033544A1 (fr) | Composé hétéroaryle substitué, composition et utilisation associées | |
WO2022007921A1 (fr) | Composé triazine, composition et utilisation associées | |
CN115515940A (zh) | 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂 | |
TW201542557A (zh) | 二氫吡咯并嘧啶衍生物 | |
WO2021233236A1 (fr) | Composé hétéroaryle substitué, composition et utilisation associées | |
US20230054411A1 (en) | 7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | |
WO2023051495A1 (fr) | Composés isoquinolinone et quinazolinone, et composition et utilisation de ceux-ci | |
CN115703770A (zh) | 嘧啶胺类化合物及其组合物和用途 | |
WO2023020486A1 (fr) | Composé inhibiteur de la kinase rip1 et composition et utilisation associées | |
WO2024067714A1 (fr) | Composés ayant une activité tumorale mutante anti-kras |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22874880 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |